<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Hereditary spherocytosis
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Hereditary spherocytosis
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Hereditary spherocytosis
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Theodosia Kalfa, MD, PhD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Robert T Means, Jr, MD, MACP
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Jennifer S Tirnauer, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Oct 25, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Although relatively rare, hereditary spherocytosis (HS) is the most common cause of hemolytic anemia due to a red cell membrane defect. It is a result of heterogeneous alterations in one of five genes that encode red blood cell (RBC) membrane proteins involved in vertical associations that link the membrane cytoskeleton to the lipid bilayer.
        </p>
        <p>
         The genetics, pathophysiology, clinical features, diagnosis, and treatment of HS will be reviewed here. Other inherited RBC membrane disorders, including hereditary elliptocytosis (HE), hereditary pyropoikilocytosis (HPP), and hereditary stomatocytosis (HSt), are discussed separately, as are general approaches to the evaluation of hemolytic anemia.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          HE and HPP
         </strong>
         – (See
         <a class="medical medical_review" href="/z/d/html/7087.html" rel="external">
          "Hereditary elliptocytosis and related disorders"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          HSt
         </strong>
         – (See
         <a class="medical medical_review" href="/z/d/html/7068.html" rel="external">
          "Hereditary stomatocytosis (HSt) and hereditary xerocytosis (HX)"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Hemolytic anemia, child
         </strong>
         – (See
         <a class="medical medical_review" href="/z/d/html/5932.html" rel="external">
          "Overview of hemolytic anemias in children"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Hemolytic anemia, adult
         </strong>
         – (See
         <a class="medical medical_review" href="/z/d/html/7076.html" rel="external">
          "Diagnosis of hemolytic anemia in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H4155002310">
         <span class="h1">
          PATHOPHYSIOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         HS is a heterogeneous group of disorders caused by variants in certain genes that encode proteins of the red blood cell (RBC) membrane and cytoskeleton  (
         <a class="graphic graphic_figure graphicRef55451" href="/z/d/graphic/55451.html" rel="external">
          figure 1
         </a>
         ); specifically, HS is caused because of inadequate vertical linkages between the cytoskeleton and the lipid bilayer of the RBC membrane  (
         <a class="graphic graphic_figure graphicRef79183" href="/z/d/graphic/79183.html" rel="external">
          figure 2
         </a>
         ) [
         <a href="#rid1">
          1,2
         </a>
         ]. The loss of vertical linkages leads to loss of RBC membrane and a spherocytic (rather than biconcave disc) shape of HS RBCs, with decreased surface-to-volume ratio and decreased deformability that is essential to the normal RBC lifespan. (See
         <a class="medical medical_review" href="/z/d/html/7091.html" rel="external">
          "Red blood cell membrane: Structure and dynamics"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3833308762">
         <span class="h2">
          Genetics
         </span>
        </p>
        <p class="headingAnchor" id="H56136727">
         <span class="h3">
          Overview of the proteins and genes involved
         </span>
         <span class="headingEndMark">
          —
         </span>
         HS is caused by quantitative deficiency of alpha- or beta-spectrin, ankyrin, protein 4.2, or band 3, encoded by the genes
         <em>
          SPTA1
         </em>
         ,
         <em>
          SPTB
         </em>
         ,
         <em>
          ANK1
         </em>
         ,
         <em>
          EPB42
         </em>
         , and
         <em>
          SLC4A1
         </em>
         , respectively [
         <a href="#rid2">
          2-4
         </a>
         ]. The studies that have evaluated specific gene variants have generally found that pathogenic variants in these genes tend to be distributed throughout the gene, producing an abundance of variants that are private to individual kindreds rather than localized to specific "hotspots"; this is illustrated in the figure  (
         <a class="graphic graphic_figure graphicRef55451" href="/z/d/graphic/55451.html" rel="external">
          figure 1
         </a>
         ) [
         <a href="#rid5">
          5-7
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Spectrin
         </strong>
         – Erythrocyte spectrin is composed of alpha-beta heterodimers; the proteins are encoded by the
         <em>
          SPTA1
         </em>
         and
         <em>
          SPTB
         </em>
         genes, respectively.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Ankyrin
         </strong>
         – Erythrocyte ankyrin is encoded by the
         <em>
          ANK1
         </em>
         gene. (See
         <a class="local">
          'Ankyrin deficiency due to ANK1 pathogenic variants'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Band 3
         </strong>
         (the anion exchanger AE1) – This anion channel is encoded by the solute carrier family 4 anion exchanger 1 (
         <em>
          SLC4A1
         </em>
         ) gene. (See
         <a class="local">
          'Band 3 deficiency due to SLC4A1 variants'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Protein 4.2
         </strong>
         (also called band 4.2) – Protein 4.2 is encoded by the
         <em>
          EPB42
         </em>
         gene. In the past, protein 4.2 was briefly referred to as pallidin, which is now recognized as a different protein [
         <a href="#rid8">
          8,9
         </a>
         ]. (See
         <a class="local">
          'Band 4.2 deficiency due to EPB42 variants'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Information from mouse models
         </strong>
         – The roles of these variants in causing spherocytosis has been studied in several genetically engineered animal models (transgenic mice) and in naturally occurring variants in mice and cattle [
         <a href="#rid10">
          10-14
         </a>
         ]. In the neonatal anemia (Nan) mouse, the variant p.E339D in
         <em>
          KLF1
         </em>
         , the gene that encodes the erythroid transcription factor Krüppel-like factor 1, results in deficiencies of multiple membrane proteins (alpha spectrin, beta spectrin, ankyrin, band 3, and band 4.1R) and clinical features of HS (spherocytic anemia) [
         <a href="#rid15">
          15,16
         </a>
         ]. The substitution p.E325K in the
         <em>
          KLF1
         </em>
         gene, corresponding to the
         <em>
          Nan
         </em>
         mutation, causes congenital dyserythropoietic anemia (CDA) type IV, with disordered erythropoiesis due to widespread transcriptomic changes affecting many more genes than the ones encoding membrane proteins [
         <a href="#rid17">
          17,18
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Methods of analysis
         </strong>
         – Quantitative evaluation of the RBC membrane proteins with electrophoresis and immunoblotting, after isolating RBC ghosts with osmotic lysis of RBCs and washing out the hemoglobin and other cytoplasmic proteins, have been used for decades to research and evaluate the protein pathology causing spherocytosis. The discovery of the structural components of the red blood cell cytoskeleton coincided and developed in parallel with the technique of sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) as a tool for protein chemistry in the 1970s [
         <a href="#rid1">
          1
         </a>
         ]. Decrease in a specific protein would be followed up later with sequencing of the corresponding gene, deepening the understanding of erythroid and protein biology along with meticulous work of many research teams around the world.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The introduction of next generation DNA sequencing to clinical diagnostics in approximately 2010 has immensely facilitated diagnosis of RBC and erythropoiesis disorders. Genotype-phenotype correlations associated with HS genes are summarized in the sections below. Additional information about the assembly of these proteins is presented separately. (See
         <a class="medical medical_review" href="/z/d/html/7091.html" rel="external">
          "Red blood cell membrane: Structure and dynamics", section on 'Composition of the membrane/cytoskeleton'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Concomitant loss of other membrane proteins
         </strong>
         – Due to the tight interactions of the RBC cytoskeleton proteins, protein chemistry frequently demonstrates a combination of protein changes. As examples:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Alpha spectrin deficiency due to
         <em>
          SPTA1
         </em>
         pathogenic variants can be associated with concomitant decreases in beta spectrin.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Ankyrin deficiency due to
         <em>
          ANK1
         </em>
         variants is accompanied by secondary spectrin deficiency due to reduced incorporation of spectrin into the membrane since ankyrin is the principal binding site for membrane spectrin [
         <a href="#rid13">
          13
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <em>
          SLC4A1
         </em>
         variants can also cause secondary band 4.2 deficiency.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Band 3 loss is a typical finding in all types of spherocytosis regardless of the genetic cause since band 3 is lost along lipid membrane during the development of spherocytes [
         <a href="#rid5">
          5
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Related, non-HS disorders
         </strong>
         – Variants affecting protein 4.1R, encoded by the
         <em>
          EPB41
         </em>
         gene, have not been reported in HS. Protein 4.1R is an integral component of the junctional complex, participating in the horizontal associations of the RBC cytoskeleton; pathogenic variants of this gene cause hereditary elliptocytosis (HE). (See
         <a class="medical medical_review" href="/z/d/html/7087.html" rel="external">
          "Hereditary elliptocytosis and related disorders"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Similarly, pathogenic variants in
         <em>
          SPTA1
         </em>
         (encodes alpha spectrin) and
         <em>
          SPTB
         </em>
         (encodes beta spectrin) that cause qualitative rather than quantitative spectrin abnormalities cause HE rather than HS. Rare pathogenic variants in
         <em>
          SPTA1
         </em>
         and
         <em>
          SPTB
         </em>
         that cause both in spectrin deficiency (a feature of HS) as well as abnormal spectrin tetramer formation (a feature of HE) cause hereditary spherocytic elliptocytosis or pyropoikilocytosis [
         <a href="#rid19">
          19-21
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7087.html" rel="external">
          "Hereditary elliptocytosis and related disorders"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Variants affecting the Rh-associated glycoprotein, encoded by the
         <em>
          RHAG
         </em>
         gene, cause overhydrated hereditary stomatocytosis, while variants in
         <em>
          PIEZO1
         </em>
         and
         <em>
          KCNN4
         </em>
         cause dehydrated hereditary stomatocytosis or xerocytosis. (See
         <a class="medical medical_review" href="/z/d/html/7068.html" rel="external">
          "Hereditary stomatocytosis (HSt) and hereditary xerocytosis (HX)"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H4237184463">
         <span class="h3">
          Inheritance patterns
         </span>
         <span class="headingEndMark">
          —
         </span>
         The following inheritance patterns are seen, in some cases related to the specific genes involved:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         HS may be inherited in an autosomal dominant fashion, caused by heterozygous pathogenic variants in
         <em>
          ANK1
         </em>
         ,
         <em>
          SLC4A1
         </em>
         , or
         <em>
          SPTB
         </em>
         , seen in approximately 65 to 70 percent of cases [
         <a href="#rid4">
          4,6
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         An additional 5 to 15 percent of cases are autosomal recessive, caused by biallelic variants in
         <em>
          SPTA1
         </em>
         ,
         <em>
          EPB42
         </em>
         , or
         <em>
          ANK1
         </em>
         [
         <a href="#rid2">
          2,22-25
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The remaining 15 to 20 percent of cases appear to be due to de novo pathogenic variants [
         <a href="#rid26">
          26-31
         </a>
         ]. Most commonly these occur in the
         <em>
          ANK1
         </em>
         gene, likely due to its high G/C content, which predisposes to slipped strand mis-pairing during DNA replication [
         <a href="#rid32">
          32
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A few cases of autosomal recessive HS associated with biallelic
         <em>
          ANK1
         </em>
         variants have been described, in which a nonsense variant occurs in trans to a promoter or intronic variant affecting levels of expression, or to a missense variant decreasing but not obliterating the incorporation of ankyrin into the cytoskeleton, leading to a severe, transfusion-dependent disease that remains amenable to treatment with splenectomy [
         <a href="#rid6">
          6
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Very rare cases of autosomal recessive HS due to biallelic
         <em>
          SLC4A1
         </em>
         variants have been reported in infants, some requiring in-utero transfusions or born prematurely with life-threatening hydrops fetalis. These infants have severe transfusion-dependent HS, not improving with splenectomy [
         <a href="#rid33">
          33,34
         </a>
         ]. Findings are similar to the most severe form of
         <em>
          SPTA1
         </em>
         -associated HS due to complete alpha-spectrin deficiency [
         <a href="#rid35">
          35
         </a>
         ]. Biallelic truly null
         <em>
          SPTB
         </em>
         variants have not been described, indicating that complete beta-spectrin deficiency may be incompatible with life [
         <a href="#rid2">
          2
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2322072687">
         <span class="h3">
          Ankyrin deficiency due to
          <i>
           ANK1
          </i>
          pathogenic variants
         </span>
         <span class="headingEndMark">
          —
         </span>
         Ankyrin is the major protein responsible for the mechanical coupling between the lipid bilayer of the RBC membrane and the underlying spectrin-based cytoskeleton. Ankyrin, along with protein 4.2, anchors the transmembrane protein complexes, composed of band 3 and the Rh-associated glycoprotein (RhAG), to the spectrin tetramers.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Over 250
         <em>
          ANK1
         </em>
         pathogenic variants have been described and included in the Human Gene Mutation Database (HGMD) [
         <a href="#rid36">
          36,37
         </a>
         ]. These include missense/nonsense variants, splicing and regulatory substitutions, small and large deletions, insertions, and duplications. Many of these variants are "private" (found in only a single kindred) [
         <a href="#rid38">
          38,39
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <em>
          ANK1
         </em>
         -associated HS is typically an autosomal dominant disease, caused by a monoallelic pathogenic variant, decreasing the expression or incorporation to the cytoskeleton of only up to 50 percent of the ankyrin normally produced. A few cases have been described with biallelic variants, causing recessive, more severe spherocytosis; in those cases (as also discussed above) a null variant is present in trans to a promoter or intronic variant, or a missense variant decreasing but not obliterating expression from that second allele or the amount of protein incorporated in the cytoskeleton. Such combinations lead to a more severe, frequently transfusion-dependent disease, but anemia is still amenable to treatment with splenectomy [
         <a href="#rid6">
          6,40
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Patients with a deletion of the short arm of chromosome 8, which contains the
         <em>
          ANK1
         </em>
         gene, have been described; these individuals have HS, intellectual disability, and other congenital anomalies [
         <a href="#rid41">
          41
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1079633997">
         <span class="h3">
          Band 3 deficiency due to
          <i>
           SLC4A1
          </i>
          variants
         </span>
         <span class="headingEndMark">
          —
         </span>
         Band 3 has two major functions. It provides cohesion between the RBC plasma membrane and the underlying cytoskeletal proteins, preventing membrane surface loss, and it exchanges bicarbonate for chloride ions, maintaining RBC water content and preventing cellular dehydration.
        </p>
        <p>
         HS due to S
         <em>
          LC4A1
         </em>
         pathogenic variants is typically an autosomal dominant disease presenting as mild hemolytic anemia or even compensated hemolysis. Documented pathogenic variants include missense and nonsense mutations, splicing and regulatory substitutions, small deletions, insertions, or indels, as well as gross deletions and insertions [
         <a href="#rid5">
          5,7,37,42-48
         </a>
         ]. Hemolysis may be aggravated by compound heterozygosity for a pathogenic variant in
         <em>
          SLC4A1
         </em>
         in trans to a low-expression band 3 allele [
         <a href="#rid49">
          49,50
         </a>
         ].
        </p>
        <p>
         Very rare cases of autosomal recessive HS due to biallelic
         <em>
          SLC4A1
         </em>
         null variants have been reported in infants requiring in-utero transfusions or born prematurely with life-threatening hydrops fetalis. These infants have severe transfusion-dependent HS, not improving with splenectomy, in addition to severe distal renal tubular acidosis (RTA) [
         <a href="#rid33">
          33,34
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2328.html" rel="external">
          "Etiology and diagnosis of distal (type 1) and proximal (type 2) renal tubular acidosis"
         </a>
         .)
        </p>
        <p>
         Variants in
         <em>
          SLC4A1
         </em>
         affecting band 3 can cause other disorders besides HS:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          SAO
         </strong>
         – A heterozygous deletion of the codons 400 to 408 is the pathogenic variant causing Southeast Asian ovalocytosis (SAO)  (
         <a class="graphic graphic_picture graphicRef95385" href="/z/d/graphic/95385.html" rel="external">
          picture 1
         </a>
         ). The molecular change is a deletion of nine amino acids spanning between the cytoplasmic and membrane domain of the band 3 protein causing inactivation of its anion exchanger function, along with a tighter attachment to ankyrin and reduced lateral mobility of the channel, likely underlying the marked rigidity of SAO RBCs [
         <a href="#rid51">
          51,52
         </a>
         ]. Details are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/142822.html" rel="external">
          "Southeast Asian ovalocytosis (SAO)"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Distal RTA
         </strong>
         – Individuals with certain
         <em>
          SLC4A1
         </em>
         pathogenic variants causing loss of the anion exchanger function of band 3 can present with an autosomal dominant or autosomal recessive form of distal RTA. Some of these individuals may have HS [
         <a href="#rid43">
          43
         </a>
         ]; however, most of them do not, since glycophorin A (GPA) present in RBCs but not kidney epithelial cells chaperones the distal RTA-causing band 3 molecules to the RBC membrane efficiently [
         <a href="#rid33">
          33,43,53-58
         </a>
         ]. Patients with SAO and distal RTA have been shown to be compound heterozygous for the SAO causing deletion (∆400-408) and a distal RTA-causing variant [
         <a href="#rid59">
          59
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/6121.html" rel="external">
          "Etiology and clinical manifestations of renal tubular acidosis in infants and children", section on 'Genetic causes'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2328.html" rel="external">
          "Etiology and diagnosis of distal (type 1) and proximal (type 2) renal tubular acidosis", section on 'Distal (type 1) RTA'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          HS due to protein 4.2 deficiency
         </strong>
         – The
         <em>
          SLC4A1
         </em>
         gene encodes the antigens of the Diego blood group system [
         <a href="#rid60">
          60
         </a>
         ]. Polymorphisms in the gene cause variability of the Diego antigens, which are important for transfusion medicine and neonatal alloimmune hemolytic anemia; however, they are not causing HS or any other RBC pathologies. A notable exception is the common polymorphism c.118G&gt;A (pGlu40Lys), named band 3 Montefiore, which in the homozygous state decreases the incorporation of protein 4.2 into the RBC cytoskeleton by approximately 88 percent, causing HS due to protein 4.2 deficiency [
         <a href="#rid61">
          61
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Cryohydrocytosis
         </strong>
         – Certain heterozygous
         <em>
          SLC4A1
         </em>
         single amino-acid substitutions in the transmembrane domain of RBC band 3 convert its function from an anion exchanger (AE1) into an unregulated cation channel, leaking intracellular K
         <sup>
          +
         </sup>
         with a temperature-dependent, passive diffusion process [
         <a href="#rid62">
          62
         </a>
         ]. Such
         <em>
          SLC4A1
         </em>
         pathogenic variants cause cryohydrocytosis, a form of hereditary stomatocytosis, where the K
         <sup>
          +
         </sup>
         leak decreases at room temperature (23°C) and increases to a maximum when the temperature approaches 5°C [
         <a href="#rid63">
          63
         </a>
         ]. This K
         <sup>
          +
         </sup>
         leak via the altered AE1 channel disturbs the osmotic balance and surface-to-volume ratio of the RBCs, leading to chronic hemolysis [
         <a href="#rid64">
          64,65
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Stomatocytosis and dyserythropoiesis
         </strong>
         – A de novo band 3 variant (p.G796R-band3 CEINGE) was shown to be associated with stomatocytosis and a dyserythropoietic anemia phenotype on bone marrow studies [
         <a href="#rid66">
          66
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         <em>
          SLC4A1
         </em>
         pathogenic variants appear to cause approximately 5 percent of HS cases. (See
         <a class="local">
          'Overview of the proteins and genes involved'
         </a>
         above.)
        </p>
        <p>
         However, this may be an underestimate since
         <em>
          SLC4A1
         </em>
         -associated HS
         <em>
         </em>
         is typically mild and infrequently investigated with clinical sequencing. As mentioned above, band 3 deficiency is a typical phenotypic finding in all types of spherocytosis regardless of the genetic cause since band 3 is lost from the RBC lipid membrane in the process of spherocyte development. (See
         <a class="local">
          'Overview of the proteins and genes involved'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H265357797">
         <span class="h3">
          Beta spectrin or alpha-spectrin deficiency due to
          <i>
           SPTB
          </i>
          or
          <i>
           SPTA1
          </i>
          pathogenic variants
         </span>
         <span class="headingEndMark">
          —
         </span>
         beta-spectrin (encoded by
         <em>
          SPTB
         </em>
         ) and alpha-spectrin (encoded by
         <em>
          SPTA1
         </em>
         ) associate in a rod-like heterodimer; two of these heterodimers associate head to head in tetramers that make the sides of each triangular unit in the hexagonal structure of the RBC cytoskeleton.
        </p>
        <p>
         While spectrin heterotetramers are the main components of the horizontal cytoskeleton, they are also critical for the vertical interactions with the lipid membrane via their binding to ankyrin/band 3 complexes  (
         <a class="graphic graphic_figure graphicRef79183" href="/z/d/graphic/79183.html" rel="external">
          figure 2
         </a>
         ). Qualitatively abnormal spectrin causes hereditary elliptocytosis (HE); conversely, quantitative decreases in the amount of spectrin produced or incorporated to the cytoskeleton due to pathogenic variants in the corresponding genes causes HS [
         <a href="#rid2">
          2,67
         </a>
         ]. Abnormalities in both the quality and the quantity of beta-spectrin or alpha-spectrin incorporated into the RBC cytoskeleton cause a mixed phenotype of spherocytic elliptocytosis/pyropoikilocytosis [
         <a href="#rid20">
          20,21
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7087.html" rel="external">
          "Hereditary elliptocytosis and related disorders", section on 'Hereditary spherocytic elliptocytosis (HSE)'
         </a>
         .)
        </p>
        <p>
         HS due to
         <em>
          SPTB
         </em>
         pathogenic variants is an autosomal dominant disease that presents as mild to moderate hemolytic anemia. Recessive disease due to truly null biallelic
         <em>
          SPTB
         </em>
         variants has not been described, indicating that complete deficiency of beta-spectrin is likely to be lethal early in embryonic life. A multitude of pathogenic variants has been described, most of them nonsense mutations, with a few missense mutations, several splicing variants, small deletions, insertions, or indels, as well as gross deletions, insertions, and complex rearrangements [
         <a href="#rid36">
          36,48,68-76
         </a>
         ].
        </p>
        <p>
         HS due to alpha-spectrin deficiency is an autosomal recessive disease. Each
         <em>
          SPTA1
         </em>
         allele produces alpha-spectrin well in excess; therefore, biallelic pathogenic variants are required in
         <em>
          SPTA1
         </em>
         to decrease production of the protein enough to cause disease [
         <a href="#rid35">
          35,77-81
         </a>
         ]. The typical genotype for this type of HS is a null
         <em>
          SPTA1
         </em>
         variant, such as a nonsense, frameshift, or splicing variant causing nonsense-mediated decay, or whole gene deletion, in trans to the deep intronic variant c.4339-99C&gt;T, also known as alpha-LEPRA (Low Expression PRAgue), which severely decreases the expression of alpha-spectrin from that
         <em>
          SPTA1
         </em>
         allele [
         <a href="#rid35">
          35,79,80
         </a>
         ]. This genotype causes severe to moderately severe, most typically transfusion-dependent HS since birth, that nevertheless responds well to splenectomy.
        </p>
        <p>
         Rare cases of autosomal recessive
         <em>
          SPTA1
         </em>
         -associated disease with biallelic pathogenic variants causing complete or almost complete alpha-spectrin deficiency may present with fatal hydrops fetalis in the third trimester of pregnancy or with life-threatening anemia in utero if pregnancy is closely monitored. These fetuses can survive to term with in-utero transfusions or if they are delivered prematurely for another reason and receive transfusions in the neonatal period. Characteristic for this disease is reticulocytopenia even when anemic, and the disease does not respond to splenectomy, requiring either lifelong transfusions with chelation therapy or treatment with hematopoietic stem cell transplant (HSCT) [
         <a href="#rid35">
          35
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2961525668">
         <span class="h3">
          Band 4.2 deficiency due to
          <i>
           EPB42
          </i>
          variants
         </span>
         <span class="headingEndMark">
          —
         </span>
         Band 4.2 (also called protein 4.2) strengthens the linkage between band 3 and ankyrin.
         <em>
          EPB42
         </em>
         -associated HS is an autosomal recessive disease. The typical patient with band 4.2 deficiency is of Japanese ancestry [
         <a href="#rid82">
          82
         </a>
         ]; however, patients of other ethnic backgrounds have also been identified [
         <a href="#rid83">
          83,84
         </a>
         ]. A number of missense and splicing mutations, as well as a few small deletions, indels, and gross deletions, have been reported [
         <a href="#rid85">
          85-90
         </a>
         ]. Other cases of band 4.2 deficiency may be secondary to a variant in S
         <em>
          LC4A1
         </em>
         (encoding band 3) that alters its binding with band 4.2 protein and/or its interactions with the cytoskeleton [
         <a href="#rid61">
          61,91-94
         </a>
         ]. As noted above, deficiencies of band 4.2 are rare causes of HS. (See
         <a class="local">
          'Overview of the proteins and genes involved'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H4028347511">
         <span class="h2">
          Changes in the RBC membrane
         </span>
         <span class="headingEndMark">
          —
         </span>
         Most of the pathogenic variants that cause HS do so by reducing the level of one or more RBC membrane proteins that link the cytoskeleton to the overlying plasma membrane. It is also possible for HS variants to affect protein-protein binding rather than protein abundance. (See
         <a class="local">
          'Overview of the proteins and genes involved'
         </a>
         above.)
        </p>
        <p>
         Studies from animal models suggest that one of the mechanisms of secondary cytoskeletal protein deficiencies involves aberrant sorting of these proteins during the enucleation stage of RBC maturation (when the nucleus is extruded, certain proteins are expelled with the extruded cell nucleus) [
         <a href="#rid95">
          95
         </a>
         ].
        </p>
        <p>
         The loss of these proteins results in reduced vertical associations between the cytoskeleton and membrane, which in turn cause microvesiculation and progressive membrane loss, the central abnormality that defines HS [
         <a href="#rid96">
          96-98
         </a>
         ]. Loss of membrane reduces the ratio of RBC surface area to volume, in turn creating progressively more spherical cells  (
         <a class="graphic graphic_picture graphicRef70611" href="/z/d/graphic/70611.html" rel="external">
          picture 2
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/7091.html" rel="external">
          "Red blood cell membrane: Structure and dynamics", section on 'Surface area to volume ratio (SA/V)'
         </a>
         .)
        </p>
        <p>
         There is evidence that membrane loss is present as early as the reticulocyte stage; this distinguishes HS from autoimmune hemolytic anemia (AIHA), in which typically only mature RBCs become spherocytic due to membrane loss [
         <a href="#rid99">
          99
         </a>
         ].
        </p>
        <p>
         Two hypotheses have been advanced to explain how deficient production or incorporation of these membrane proteins lead to vesiculation and membrane loss. In the first, spectrin deficiency acts directly on the bilayer to create areas of weakness that allow membrane loss. In the second, band 3 deficiency or dispersion causes vesiculation by reducing the integrity of the lipid bilayer [
         <a href="#rid100">
          100
         </a>
         ].
        </p>
        <p>
         Some individuals with HS have abnormal RBC ion transport, the severity of which may depend on the degree of band 3 (also known as anion exchanger 1 [AE1]) deficiency [
         <a href="#rid101">
          101
         </a>
         ]. On the other hand, all spherocytes demonstrate increased passive permeability to monovalent cations (sodium and potassium) [
         <a href="#rid101">
          101,102
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7068.html" rel="external">
          "Hereditary stomatocytosis (HSt) and hereditary xerocytosis (HX)", section on 'Control of RBC solute and water content'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1623571274">
         <span class="h2">
          Mechanisms of hemolysis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Spherocytes are prone to hemolysis. The mechanisms include reduced deformability, which impairs passage through constricted regions of the microcirculation, hemolysis within the splenic microenvironment, and/or phagocytosis by the splenic red pulp macrophages, which may occur in response to splenic trapping [
         <a href="#rid103">
          103,104
         </a>
         ].
        </p>
        <p>
         Loss of spectrin appears to be especially correlated with the severity of hemolysis [
         <a href="#rid105">
          105
         </a>
         ]; this is seen in the extreme case of severe reticulocytopenia and hemolysis of nascent reticulocytes within the bone marrow in cases of complete alpha-spectrin deficiency [
         <a href="#rid35">
          35
         </a>
         ]. (See
         <a class="local">
          'Beta spectrin or alpha-spectrin deficiency due to SPTB or SPTA1 pathogenic variants'
         </a>
         above.)
        </p>
        <p>
         Once RBCs become spherocytic, successive phagocytosis during repeated passages through the splenic cords (a process termed splenic conditioning) promotes further membrane loss and a progressively more spheroidal shape  (
         <a class="graphic graphic_picture graphicRef70611" href="/z/d/graphic/70611.html" rel="external">
          picture 2
         </a>
         ). (See
         <a class="local">
          'Changes in the RBC membrane'
         </a>
         above.)
        </p>
        <p>
         This in turn further impairs passage through the narrow fenestrations of the splenic cords [
         <a href="#rid103">
          103,106
         </a>
         ]. The mechanics of passage through the splenic cords and the effect on spherocytes has been simulated using a two-component RBC model [
         <a href="#rid107">
          107
         </a>
         ]. In severe cases, reduced membrane stability may contribute to mechanical RBC destruction.
        </p>
        <p>
         In addition to phagocytosis, the spleen also exposes RBCs to an acidotic, oxidizing, metabolically unfavorable environment. RBCs may also become depleted of 2,3-bisphosphoglycerate (2,3-BPG; also called 2,3-diphosphoglycerate [2,3-DPG]), and in certain cases, there may be methylation of membrane proteins (in spectrin deficiency but not in band 3 deficiency) [
         <a href="#rid108">
          108
         </a>
         ].
        </p>
        <p>
         Case reports have described individuals with the same familial variant who have different severities of hemolysis (variable clinical penetrance). In some cases, this variability has been attributed to concomitant variants in other genes that affect RBC structure and function. As an example, in a family with mild autosomal dominant HS due to partial band 3 deficiency, one family member had more severe clinical features than others, and this was attributed to an exacerbating effect of a variant in
         <em>
          PKLR
         </em>
         , which encodes pyruvate kinase (PK) [
         <a href="#rid109">
          109
         </a>
         ]. It was speculated that low ATP levels from his partial PK deficiency increased the osmotic fragility of his RBCs. A study from Germany found that PK activity in RBCs from patients with HS were relatively low, particularly in reticulocytes [
         <a href="#rid110">
          110
         </a>
         ]. Loss of membrane-associated PK was proposed to be responsible and might contribute to the severity of HS. Further studies are needed.
        </p>
        <p>
         As discussed below, splenectomy can virtually eliminate hemolysis and anemia in almost all cases of HS, with the exception of the most severe forms due to complete or almost complete alpha-spectrin or complete band 3 deficiency. The role of splenectomy in HS management is discussed below. (See
         <a class="local">
          'Splenectomy'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H15480082">
         <span class="h1">
          EPIDEMIOLOGY
         </span>
        </p>
        <p class="headingAnchor" id="H4192621965">
         <span class="h2">
          Disease prevalence
         </span>
         <span class="headingEndMark">
          —
         </span>
         HS is seen in all populations but appears to be especially common in people of northern European ancestry. In these individuals, HS affects as many as 1 in 2000 to 1 in 5000 (prevalence, approximately 0.02 to 0.05 percent) [
         <a href="#rid22">
          22,23,97,111
         </a>
         ].
        </p>
        <p>
         The frequency is thought to be lower in individuals from other parts of the world such as Africa and Southeast Asia, although comprehensive population survey data are unavailable.
        </p>
        <p>
         In a 2006 study that tested 402 severely jaundiced neonates (requiring phototherapy), four (1 percent) were ultimately diagnosed with HS (ie, approximately 20 times more prevalent than in the general population; approximately one-fifth as prevalent as acquired, immune-mediated spherocytosis) [
         <a href="#rid112">
          112
         </a>
         ]. Other causes of neonatal jaundice and the evaluation of a neonate suspected to have HS are presented below. (See
         <a class="local">
          'Neonates'
         </a>
         below and
         <a class="local">
          'Differential diagnosis'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H1214230394">
         <span class="h2">
          Frequency of different genetic variants
         </span>
         <span class="headingEndMark">
          —
         </span>
         Cohort studies providing relative frequencies of the genes contributing to HS pathogenesis in different populations include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a study of 166 children with HS in Canada, a pathogenic variant was identified in 160 of 166 (97 percent) [
         <a href="#rid48">
          48
         </a>
         ]. The percentages of pathogenic variants were seen:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <em>
          ANK1
         </em>
         – 49 percent
         <em>
         </em>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <em>
          SPTB
         </em>
         – 33 percent
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <em>
          SLC4A1
         </em>
         – 13 percent
         <em>
         </em>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <em>
          SPTA1
         </em>
         – 5 percent
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a study of 113 patients with HS from 73 families in India, the variants identified included de novo and dominantly inherited variants in the following genes [
         <a href="#rid68">
          68
         </a>
         ]:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <em>
          ANK1
         </em>
         – 53 percent
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <em>
          SPTB
         </em>
         – 36 percent
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <em>
          SLC4A1
         </em>
         – 4 percent
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Compound heterozygous variants in
         <em>
          SPTA1
         </em>
         causing autosomal recessive disease were identified in 6 percent.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a study of 95 patients in the Netherlands evaluated by next-generation sequencing (NGS) performed in the University Medical Center Utrecht Laboratory, a pathogenic variant was identified in 85 (89 percent) [
         <a href="#rid113">
          113
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <em>
          SPTA1
         </em>
         – 36 percent, possibly representing a bias of ordering genetic testing in patients with the severe phenotype of
         <em>
          SPTA1
         </em>
         -associated HS
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <em>
          ANK1
         </em>
         – 27 percent
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <em>
          SPTB
         </em>
         – 20 percent
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Another study identified autosomal recessive HS due to biallelic pathogenic variants
         <em>
          EPB42
         </em>
         in individuals of Japanese ancestry [
         <a href="#rid85">
          85,86
         </a>
         ]. Sporadic cases have also been described in patients of European ancestry [
         <a href="#rid83">
          83,84
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          CLINICAL PRESENTATION
         </span>
        </p>
        <p class="headingAnchor" id="H1295833016">
         <span class="h2">
          Disease severity and age of presentation
         </span>
         <span class="headingEndMark">
          —
         </span>
         HS can present at any age and with any severity, with case reports describing a range of presentations from hydrops fetalis in utero through diagnosis in the ninth decade of life [
         <a href="#rid97">
          97,100,114-116
         </a>
         ].
        </p>
        <p>
         The majority of affected individuals have mild or moderate hemolysis or hemolytic anemia and a known family history, making diagnosis and treatment relatively straightforward [
         <a href="#rid98">
          98
         </a>
         ]. Individuals with significant hemolysis may develop additional complications such as jaundice/hyperbilirubinemia/cholelithiasis (typically exacerbated with concurrent Gilbert syndrome), folate deficiency, or splenomegaly [
         <a href="#rid117">
          117
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H651959770">
         <span class="h2">
          Hemolytic anemia
         </span>
         <span class="headingEndMark">
          —
         </span>
         A classification for HS has been developed based on the severity of anemia and markers of hemolysis (reticulocyte count and bilirubin) [
         <a href="#rid4">
          4,35,86,98,118
         </a>
         ].
        </p>
        <p>
         Neonates frequently present with neonatal jaundice that is noted to rise in the first day of life, posing a risk of kernicterus if not monitored and treated appropriately. However, they have a normal hemoglobin at birth. Anemia ensues after two to three weeks as the normal neonatal hyposplenism resolves; hemoglobin frequently decreases enough to require transfusion [
         <a href="#rid2">
          2,119
         </a>
         ].
        </p>
        <p>
         Transfusion dependence in the first 9 to 12 months of life, when the erythropoietic response may not be adequate, is not necessarily prognostic of the disease severity [
         <a href="#rid120">
          120,121
         </a>
         ]. Infants with an autosomal dominant form of HS based on family history and/or genetic evaluation who require frequent transfusions during the first year of life may benefit from erythropoietin administration [
         <a href="#rid122">
          122
         </a>
         ]. Transfusion dependence beyond the first year of life is not expected for autosomal dominant HS or the autosomal recessive HS due to
         <em>
          EPB41
         </em>
         biallelic pathogenic variants, but it is almost always the case for
         <em>
          SPTA1
         </em>
         -associated autosomal recessive HS. Red blood cell (RBC) indices are described below. (See
         <a class="local">
          'Initial testing'
         </a>
         below.)
        </p>
        <p>
         In older children and adults, the presentation may be that of an incidental finding of hemolysis, hemolytic anemia, or spherocytes on the blood smear  (
         <a class="graphic graphic_picture graphicRef70611" href="/z/d/graphic/70611.html" rel="external">
          picture 2
         </a>
         ), or the individual may be symptomatic with anemia, splenomegaly, pigment gallstones, or jaundice. Jaundice due to severe hemolysis is less common after the newborn period, but scleral icterus is not rare, especially when the patient also has Gilbert syndrome [
         <a href="#rid117">
          117
         </a>
         ]. (See
         <a class="local">
          'Older children and adults'
         </a>
         below.)
        </p>
        <p>
         In some cases, co-inheritance of another disorder affecting RBC survival such as sickle cell disease or thalassemia can influence the severity of anemia and make diagnosis more challenging [
         <a href="#rid118">
          118
         </a>
         ]. (See
         <a class="local">
          'Evaluation'
         </a>
         below.)
        </p>
        <p>
         Exacerbations of anemia may also occur in certain settings:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Infections
         </strong>
         – Infections that impair erythropoiesis in the bone marrow and thus diminish the capacity to compensate for chronic hemolysis may lead to a period of aplasia. A commonly cited cause of transient aplastic crisis is parvovirus B19 infection; other viral or bacterial infections may also cause transient aplasia. This is because individuals with chronic hemolysis are highly dependent on the accelerated production of new RBCs by the bone marrow, and they can experience a rapid drop in hemoglobin level when the bone marrow is unable to compensate for hemolysis.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In a series of individuals with hereditary hemolytic anemias who presented to the hospital with acute parvovirus infection, common manifestations included fever, musculoskeletal pains, and pancytopenia, while acute kidney injury was also reported, likely due to inadequate supportive management [
         <a href="#rid123">
          123
         </a>
         ]. If an individual with HS develops a precipitous decline in hemoglobin level or reticulocyte count, testing for parvovirus infection is recommended. (See
         <a class="medical medical_review" href="/z/d/html/8272.html" rel="external">
          "Clinical manifestations and diagnosis of parvovirus B19 infection"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Infections may also exacerbate hemolysis, causing worsening of anemia even with increased reticulocyte count and parallel increase of bilirubin and lactate dehydrogenase (LDH). EBV or CMV infection, which typically cause splenomegaly  (
         <a class="graphic graphic_table graphicRef69397" href="/z/d/graphic/69397.html" rel="external">
          table 1
         </a>
         ), may cause increased splenic pooling of RBCs and/or increased hemolysis (hemolytic crisis) in patients with HS or other underlying hereditary hemolytic anemias. (See
         <a class="medical medical_review" href="/z/d/html/7134.html" rel="external">
          "Splenomegaly and other splenic disorders in adults", section on 'Splenomegaly'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Nutrient deficiencies
         </strong>
         – Individuals who become deficient in folate, vitamin B12, or iron may be unable to produce sufficient RBCs to compensate for those destroyed by hemolysis. (See
         <a class="medical medical_review" href="/z/d/html/7155.html" rel="external">
          "Clinical manifestations and diagnosis of vitamin B12 and folate deficiency"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5925.html" rel="external">
          "Iron deficiency in infants and children &lt;12 years: Screening, prevention, clinical manifestations, and diagnosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5350.html" rel="external">
          "Iron requirements and iron deficiency in adolescents"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7150.html" rel="external">
          "Causes and diagnosis of iron deficiency and iron deficiency anemia in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Pregnancy
         </strong>
         – Anemia may worsen during pregnancy as the RBC mass and plasma volume expand to meet the physiologic needs of the pregnancy. Attention to
         <a class="drug drug_general" data-topicid="8475" href="/z/d/drug information/8475.html" rel="external">
          folic acid
         </a>
         supplementation is especially important during pregnancy to avoid increased risk of neural tube defects in the fetus and superimposed megaloblastic anemia for the mother [
         <a href="#rid124">
          124,125
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Iron deficiency is rare in hereditary spherocytosis, as in all hereditary hemolytic anemias; therefore, attention must be paid to avoid oral iron supplementation during pregnancy when iron overload may actually be present [
         <a href="#rid124">
          124,126
         </a>
         ]. (See
         <a class="local">
          'Overview of treatment'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p>
         Individuals who experience a decline from their baseline hemoglobin level and/or reduction in baseline reticulocyte count are likely to require more frequent monitoring and/or additional testing, details of which will depend on the associated symptoms and laboratory findings.
        </p>
        <p class="headingAnchor" id="H768278220">
         <span class="h2">
          Complications of hemolysis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Common complications of hemolysis in individuals with HS include neonatal jaundice, splenomegaly, and pigment gallstones, which are discussed in the sections that follow. (See
         <a class="local">
          'Neonatal jaundice'
         </a>
         below and
         <a class="local">
          'Splenomegaly'
         </a>
         below and
         <a class="local">
          'Pigment gallstones'
         </a>
         below.)
        </p>
        <p>
         Rarely, hemolysis may be severe enough to cause extramedullary hematopoiesis and/or growth delay, along with iron overload due to increased iron absorption and/or transfusions [
         <a href="#rid127">
          127,128
         </a>
         ]. The majority of patients with HS are not thought to be in risk of iron overload [
         <a href="#rid97">
          97
         </a>
         ]; however, there are no extensive studies of older patients, and some cases with iron overload associated with autosomal dominant HS have been reported [
         <a href="#rid129">
          129
         </a>
         ].
        </p>
        <p>
         Other rare complications that have been reported include leg ulcers, priapism, neuromuscular disorders, cardiac disease, and gout; in some cases, these may represent coincidental rather than causal associations [
         <a href="#rid97">
          97,130,131
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3066126249">
         <span class="h3">
          Neonatal jaundice
         </span>
         <span class="headingEndMark">
          —
         </span>
         HS may present in the neonatal period with jaundice and hyperbilirubinemia, and the serum bilirubin level may not peak until several days after birth. (See
         <a class="local">
          'Disease severity and age of presentation'
         </a>
         above.)
        </p>
        <p>
         Some experts have proposed that HS is underdiagnosed as a cause of neonatal jaundice [
         <a href="#rid132">
          132
         </a>
         ]. A requirement for phototherapy and/or exchange transfusion during this period is common [
         <a href="#rid97">
          97,120
         </a>
         ]. (See
         <a class="local">
          'Neonates'
         </a>
         below.)
        </p>
        <p>
         Hyperbilirubinemia may be exacerbated by concomitant Gilbert syndrome. (See
         <a class="medical medical_review" href="/z/d/html/5020.html" rel="external">
          "Unconjugated hyperbilirubinemia in neonates: Etiology and pathogenesis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2456513631">
         <span class="h3">
          Splenomegaly
         </span>
         <span class="headingEndMark">
          —
         </span>
         Splenomegaly is rare in neonates but can often be seen in older children and adults with HS [
         <a href="#rid119">
          119
         </a>
         ]. Early reports of family studies found palpable spleens in over three-fourths of affected members, but this may reflect a skewed population with the most severe disease. In these studies, the relationship between disease severity and splenic size was not linear [
         <a href="#rid133">
          133
         </a>
         ].
        </p>
        <p>
         There is no evidence of an increased risk of splenic rupture.
        </p>
        <p>
         Indications for splenectomy in HS and possible complications are discussed below. (See
         <a class="local">
          'Splenectomy'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H2041475988">
         <span class="h3">
          Pigment gallstones
         </span>
         <span class="headingEndMark">
          —
         </span>
         Pigment (bilirubin) gallstones are common in individuals with HS and may be the presenting finding in adults. Gallstones are unlikely before the age of 10 years but are seen in as many as 50 percent of adults, especially those with more severe hemolysis [
         <a href="#rid134">
          134
         </a>
         ]. Gallstones appear to be more common and tend to appear earlier in individuals with Gilbert syndrome (inherited disorder of bilirubin glucuronidation) [
         <a href="#rid117">
          117
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/3578.html" rel="external">
          "Gilbert syndrome", section on 'Long-term complications'
         </a>
         .)
        </p>
        <p>
         Obstructive jaundice or cholecystitis is treated similarly to that in individuals without HS. If cholecystectomy is performed, it may be worthwhile to discuss whether splenectomy was also planned, as the procedures could be combined; however, splenectomy should not be routinely performed during cholecystectomy [
         <a href="#rid118">
          118,135-137
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H15480294">
         <span class="h1">
          EVALUATION
         </span>
        </p>
        <p class="headingAnchor" id="H380288930">
         <span class="h2">
          When to suspect HS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The diagnosis of HS should be suspected in an individual with direct antiglobulin test (DAT; Coombs test)-negative (non-immune) hemolytic anemia and spherocytes on the peripheral blood smear. A positive family history of HS or negative testing for other inherited hemolytic anemias increases suspicion for HS. Severe disease can present in the neonatal period, whereas mild or compensated HS may not present until adulthood. (See
         <a class="local">
          'Disease severity and age of presentation'
         </a>
         above.)
        </p>
        <p>
         Typical findings of hemolytic anemia include low hemoglobin level, high reticulocyte count, high lactate dehydrogenase (LDH) and bilirubin, and low haptoglobin. (See
         <a class="medical medical_review" href="/z/d/html/7076.html" rel="external">
          "Diagnosis of hemolytic anemia in adults", section on 'Laboratory confirmation of hemolysis'
         </a>
         .)
        </p>
        <p>
         If hemolysis is severe, the patient may have jaundice (including neonatal jaundice). If compensation is insufficient (if the bone marrow cannot produce new red blood cells [RBCs] with sufficient rapidity to compensate for hemolyzed RBCs), there may be symptoms of anemia. (See
         <a class="medical medical_review" href="/z/d/html/5020.html" rel="external">
          "Unconjugated hyperbilirubinemia in neonates: Etiology and pathogenesis", section on 'Increased production'
         </a>
         .)
        </p>
        <p>
         HS is a non-immune form of hemolysis; the DAT is negative. (See
         <a class="medical medical_review" href="/z/d/html/5932.html" rel="external">
          "Overview of hemolytic anemias in children", section on 'Intrinsic hemolytic anemias'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7076.html" rel="external">
          "Diagnosis of hemolytic anemia in adults", section on 'Immune versus non-immune'
         </a>
         .)
        </p>
        <p>
         Findings that suggest an alternative diagnosis include prior normal complete blood counts (CBCs) and hemolysis markers. It must be noted that 3 to 11 percent of autoimmune hemolytic anemias may be DAT-negative, depending on the sensitivity of the assay [
         <a href="#rid138">
          138,139
         </a>
         ]. A high-index of suspicion for DAT-negative autoimmune hemolytic anemia (AIHA) must be maintained for a patient presenting with hemolytic anemia with no prior personal and family history, especially with microspherocytes on the smear and other evidence of immune dysregulation [
         <a href="#rid140">
          140
         </a>
         ].
        </p>
        <p>
         Evaluation of the peripheral blood smear is very helpful; obvious RBC abnormalities may suggest a different type of hemolytic anemia (eg, stomatocytes, ovalocytes, target cells, sickle cells). (See
         <a class="medical medical_review" href="/z/d/html/4435.html" rel="external">
          "Evaluation of the peripheral blood smear", section on 'Permutation in shape'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H11594793">
         <span class="h2">
          Initial testing
         </span>
        </p>
        <p class="headingAnchor" id="H3711739581">
         <span class="h3">
          All patients
         </span>
         <span class="headingEndMark">
          —
         </span>
         Some aspects of the initial evaluation differ in neonates versus older children and adults since affected neonates tend to have more severe disease and less useful laboratory parameters. (See
         <a class="local">
          'Neonates'
         </a>
         below.)
        </p>
        <p>
         However, the following are appropriate in virtually all individuals:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          CBC and RBC indices
         </strong>
         – All individuals with suspected HS based on family history, neonatal jaundice, or other findings should have a complete blood count (CBC) with reticulocyte count and RBC indices. The mean corpuscular hemoglobin concentration (MCHC) is often the most useful parameter for assessing spherocytosis; an MCHC ≥36 g/dL is consistent with spherocytes. A normal mean corpuscular volume (MCV) is expected, with a wide (increased) red cell distribution width (RDW); significant reticulocytosis may increase the MCV.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Blood smear review
         </strong>
         – All individuals with suspected HS should have a blood smear reviewed by an experienced individual. RBC parameters to be assessed include the presence and abundance of spherocytes, other abnormal RBC shapes, and the degree of polychromatophilia, which reflects reticulocytosis.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Hemolysis testing
         </strong>
         – Testing for hemolysis is also appropriate in all patients. This includes lactate dehydrogenase (LDH), indirect bilirubin, haptoglobin, and reticulocyte count. Findings consistent with hemolysis include increased LDH and indirect bilirubin, decreased or absent haptoglobin, and an elevated reticulocyte count.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Coombs testing
         </strong>
         – If hemolysis is present, a DAT should be done to evaluate for the possibility of immune-mediated hemolysis, which may be due to hemolytic disease of the fetus and newborn (HDFN) in neonates or autoimmune hemolytic anemia (AIHA) in older children and adults.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The results of testing may also be useful to the transfusion service if transfusion is indicated. The DAT in HS is negative. It should be noted that 3 to 11 percent of AIHAs may also be DAT-negative, depending on the sensitivity of the assay [
         <a href="#rid138">
          138,139
         </a>
         ]. Therefore, a high-index of suspicion for DAT-negative AIHA is indicated for a patient presenting with hemolytic anemia with no prior personal and family history, especially with presence of microspherocytes on the smear and other evidence of immune dysregulation [
         <a href="#rid140">
          140
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         Our approach to the evaluation is consistent with a 2011 guideline (published in 2012) from the British Committee for Standards in Haematology (BCSH) on the diagnosis of HS and a 2015 guideline from the International Council for Standardization in Haematology (ICSH) on non-immune hereditary RBC membrane disorders [
         <a href="#rid118">
          118,141
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3826602720">
         <span class="h3">
          Neonates
         </span>
         <span class="headingEndMark">
          —
         </span>
         Neonates with severe hemolysis due to HS may present with neonatal jaundice. (See
         <a class="local">
          'Disease severity and age of presentation'
         </a>
         above.)
        </p>
        <p>
         The evaluation of a neonate with suspected HS depends on whether a parent is known to have HS.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         If an infant with hyperbilirubinemia or other findings of non-immune hemolytic anemia has a known family history of HS, then the likelihood of HS is high, and we rely heavily on the RBC indices. As noted above, an MCHC ≥36 g/dL is highly suggestive of HS. (See
         <a class="local">
          'Clinical presentation'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         If an infant with hyperbilirubinemia or hemolytic anemia does not have a known family history of HS, then a number of other possible diagnoses must be considered. (See
         <a class="local">
          'Differential diagnosis'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p>
         Appropriate therapy should not be delayed while determining the underlying cause; likewise, the importance of making the diagnosis of HS should be emphasized regardless of the management interventions needed. Hemolytic anemia with a negative DAT and a high MCHC (eg, ≥36 g/dL) is consistent with HS but must be considered in the context of the entire clinical picture. (See
         <a class="local">
          'Confirmatory tests'
         </a>
         below and
         <a class="medical medical_review" href="/z/d/html/5020.html" rel="external">
          "Unconjugated hyperbilirubinemia in neonates: Etiology and pathogenesis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5008.html" rel="external">
          "Unconjugated hyperbilirubinemia in term and late preterm newborns: Screening"
         </a>
         .)
        </p>
        <p>
         Neonates with HS tend to have an elevated MCHC (typical range in HS, 35 to 38 g/dL) [
         <a href="#rid119">
          119
         </a>
         ]. This is a useful discriminator between HS and hemolytic disease of the fetus and newborn (HDFN) because HDFN RBCs tend to have MCHC in the range of 33 to 36 g/dL [
         <a href="#rid132">
          132
         </a>
         ].
        </p>
        <p>
         Spherocytes on the blood smear are helpful if present, but up to one-third of neonates with HS do not have prominent spherocytes, and some neonates without HS have spherocytes [
         <a href="#rid119">
          119
         </a>
         ]. In addition, it may be difficult to assess spherocytes on the peripheral blood smear in a neonate, either because neonates with HS may have fewer spherocytes or because spherocytic cells are often present after birth in neonates without HS [
         <a href="#rid141">
          141
         </a>
         ].
        </p>
        <p>
         If the infant is well, it is reasonable to postpone testing until approximately six months of age or older, at which time the RBC morphology will be easier to assess [
         <a href="#rid118">
          118
         </a>
         ]. If there is greater urgency to establish a diagnosis (eg, severe anemia or hyperbilirubinemia), specialized testing may be used. (See
         <a class="local">
          'Confirmatory tests'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H1061139475">
         <span class="h3">
          Older children and adults
         </span>
         <span class="headingEndMark">
          —
         </span>
         As noted above, HS may be suspected in a patient of any age who has evidence of hemolysis (eg, elevated serum LDH, elevated indirect bilirubin, reduced haptoglobin, increased reticulocyte count) or hemolytic anemia that is DAT-negative and not explained by another condition.
        </p>
        <p>
         HS may also be suspected in an individual who presents with a complication of hemolysis, such as splenomegaly, pigmented gallstones, or an abrupt drop in hemoglobin level when the bone marrow cannot compensate for hemolysis (eg, during a viral illness, pregnancy, or other condition). In such cases, a CBC will be obtained and RBC indices will be available; the reticulocyte count should also be measured if not done already.
        </p>
        <p>
         Evidence consistent with HS as the likely diagnosis in an older child or adult include the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Positive family history of HS, although this is not always present as some cases arise as de novo pathogenic variants and not all individuals will have a complete family history available.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Chronic hemolytic anemia, although in mild cases, there may be chronic compensated hemolysis without anemia. The typical reticulocyte count in older children and adults with HS is approximately 5 to 20 percent, but it may be as high as 20 to 30 percent in severe cases.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Jaundice and/or splenomegaly, although these may be absent if the hemolysis is mild.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Spherocytes  (
         <a class="graphic graphic_picture graphicRef70611" href="/z/d/graphic/70611.html" rel="external">
          picture 2
         </a>
         ) on the peripheral blood smear. The percentage of spherocytes is variable. Pathogenic variants in certain genes have been associated with specific spherocyte morphologies, although the diagnostic value of these findings has not been rigorously tested [
         <a href="#rid5">
          5,69,70,142,143
         </a>
         ] (see
         <a class="local">
          'Genetics'
         </a>
         above):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Anisocytic spherocytes – Ankyrin deficiency
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Pincered or mushroom-shaped spherocytes – Band 3 deficiency
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Acanthocytic spherocytes – Beta spectrin deficiency
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Dense and irregularly shaped cells – Alpha spectrin deficiency
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Ovalocytes and occasional ovalostomatocytes – Protein 4.2 deficiency
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         RBC indices consistent with spherocytosis (eg, MCHC &gt;36 g/dL; normal MCV with wide red cell distribution width [RDW]). The MCV and RDW may be increased by greater degrees of reticulocytosis in older children and adults; thus, the MCHC is the most useful of the RBC indices.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The combination of increased MCHC and increased RDW further improves diagnostic performance [
         <a href="#rid144">
          144
         </a>
         ]. If reticulocyte indices are available, a higher-than-average reticulocyte MCHC and a low reticulocyte MCV are also consistent with HS  (
         <a class="graphic graphic_table graphicRef54945" href="/z/d/graphic/54945.html" rel="external">
          table 2
         </a>
         ) [
         <a href="#rid118">
          118
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         In the appropriate clinical setting, these observations may be sufficient to screen for a diagnosis of HS. (See
         <a class="local">
          'Diagnosis'
         </a>
         below.)
        </p>
        <p>
         In cases that are unclear or if there are questions about the prognosis or if splenectomy is being considered, additional diagnostic confirmation is needed, especially to avoid misdiagnosis of hereditary xerocytosis as HS. The following specialized testing can be pursued. (See
         <a class="local">
          'Confirmatory tests'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H8">
         <span class="h2">
          Confirmatory tests
         </span>
         <span class="headingEndMark">
          —
         </span>
         A number of tests are available for confirming the diagnosis of HS.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          EMA binding
         </strong>
         – Eosin-5-maleimide (EMA) binding is a good and widely available test for HS diagnosis; it detects loss mainly of band 3 and Rh-related proteins from the RBC membrane, using EMA, an eosin-based fluorescent dye, that binds to those RBC membrane proteins [
         <a href="#rid145">
          145
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The mean fluorescence of EMA-labeled RBCs from individuals with HS is lower than controls, and this reduction in fluorescence can be detected in a flow cytometry-based assay, as illustrated in the figure  (
         <a class="graphic graphic_figure graphicRef131252" href="/z/d/graphic/131252.html" rel="external">
          figure 3
         </a>
         ). The reduction in EMA binding is observed in RBCs when HS is due to band 3 deficiency or to deficiencies in other proteins such as ankyrin or spectrin, since the common characteristic in HS is loss of membrane along with band 3 complexes [
         <a href="#rid146">
          146
         </a>
         ]. Two case series of individuals with HS have found the EMA fluorescence in individuals with HS to be approximately two-thirds that of controls [
         <a href="#rid145">
          145,147
         </a>
         ]. Samples can be stored and tested; one of the studies also analyzed the effect of delayed testing and found that samples stored for 24 hours in the darkness gave similar results to those tested immediately [
         <a href="#rid145">
          145
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Advantages of EMA binding include its high sensitivity; rapid turnaround time (approximately two hours); and need for only a minimal amount of blood (a few microliters), which is especially advantageous for testing neonates [
         <a href="#rid148">
          148-150
         </a>
         ]. EMA testing can also be used to evaluate for HS-RBCs in a specimen from a patient who has recently received a transfusion [
         <a href="#rid151">
          151
         </a>
         ]. In various studies, the sensitivity and specificity of the test to diagnose HS versus normal RBCs appear to be in the ranges of 93 to 96 and 93 to 99 percent, respectively [
         <a href="#rid148">
          148,152-154
         </a>
         ]. It is important in testing neonatal RBCs to compare the results of EMA binding to control samples from age-matched controls [
         <a href="#rid155">
          155
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         However, when EMA results for HS are compared with those for other RBC membrane disorders, the specificity of the test declines. EMA binding is also decreased (ie, the test is considered positive) in other hemolytic anemias with loss of membrane associated with band 3 complexes, such as hereditary pyropoikilocytosis, spherocytic elliptocytosis/pyropoikilocytosis, Southeast Asian ovalocytosis (SAO), autoimmune hemolytic anemia, as well as congenital dyserythropoietic anemia (CDA) type II [
         <a href="#rid147">
          147,152,156
         </a>
         ]. False-negative results may be seen in mild cases of HS. (See
         <a class="local">
          'Differential diagnosis'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Osmotic fragility
         </strong>
         – Osmotic fragility testing (OFT) is a traditional, specialized test for HS, based on the fact that spherocytic RBCs have reduced surface area to volume (SA/V) ratio. In this test, fresh RBCs are incubated in hypotonic buffered salt solutions of various osmolarities, and the fraction of hemoglobin released (due to hemolysis) is measured. The test takes advantage of the increased sensitivity of spherocytes to hemolysis due to their reduced SA/V ratio  (
         <a class="graphic graphic_figure graphicRef69042" href="/z/d/graphic/69042.html" rel="external">
          figure 4
         </a>
         ). Incubation of patient samples for 24 hours prior to testing may accentuate osmotic fragility and improve diagnostic yield.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The OFT has relatively low sensitivity and specificity. It fails to identify a significant number of individuals with HS, and, particularly in the newborn, it may be positive in other conditions including immune hemolytic anemia, hemolytic transfusion reactions, RBC enzyme deficiencies such as glucose-6-phosphate dehydrogenase (G6PD) deficiency, and unstable hemoglobin variants [
         <a href="#rid141">
          141
         </a>
         ]. In one series of 86 individuals with HS, only 57 (66 percent) had positive osmotic fragility testing [
         <a href="#rid157">
          157
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Osmotic gradient ektacytometry
         </strong>
         – Osmotic gradient ektacytometry (OGE) is the reference method to evaluate RBC membrane disorders [
         <a href="#rid158">
          158,159
         </a>
         ]. It offers accurate (with 100 percent assay sensitivity) diagnosis of HS and excellent specificity in differential diagnosis between the various RBC membrane disorders, including hydration defects   (
         <a class="graphic graphic_figure graphicRef131252" href="/z/d/graphic/131252.html" rel="external">
          figure 3
         </a>
         ) [
         <a href="#rid2">
          2,81,156
         </a>
         ]. The assay evaluates the deformability of RBCs as they are subjected to constant shear stress in a medium of increasing osmolality in a laser diffraction viscometer. The testing has become more accessible over the last decade with the commercial availability of a new generation ektacytometer) [
         <a href="#rid156">
          156,160
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Limitations of OGE include its decreased sensitivity after recent transfusions, as with all phenotypic tests that evaluate RBCs as a population. Warm AIHA with a significant number of microspherocytes and CDA-II may produce an ektacytometry curve resembling HS [
         <a href="#rid2">
          2,81
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Glycerol lysis
         </strong>
         – The glycerol lysis test (GLT) and the acidified GLT (AGLT) are modifications of the OFT that add glycerol (in the GLT) or glycerol plus
         <a class="drug drug_general" data-topicid="10269" href="/z/d/drug information/10269.html" rel="external">
          sodium phosphate
         </a>
         (to lower the pH to 6.85, in the AGLT) to the hypotonic buffered salt solutions in which the patient's RBCs are incubated [
         <a href="#rid111">
          111,141
         </a>
         ]. Like EMA, OFT, and OGE, these tests may also be positive in acquired spherocytosis conditions such as AIHA.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The "pink test" is a modification of the GLT in which the final extent of hemolysis is measured in a blood sample incubated in the glycerol solution at pH 6.66 [
         <a href="#rid161">
          161
         </a>
         ]. A further modification has been proposed (the direct pink test) in which the test sample is obtained from fingerprick (or heel puncture in newborns), rather than venipuncture, and incubated directly in the glycerol solution; this requires only a few microliters of blood [
         <a href="#rid162">
          162
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Cryohemolysis
         </strong>
         – In the cryohemolysis test, RBCs are suspended in a hypertonic solution, briefly heated to 37°C, then cooled to 4°C for 10 minutes [
         <a href="#rid163">
          163
         </a>
         ]. Ease of performance and the wide separation in degree of hemolysis between spherocytes and normal cells are two attractive features of this test [
         <a href="#rid164">
          164
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         The last two tests (glycerol lysis and cryohemolysis) have limited availability in the United States.
        </p>
        <p>
         The relative performance of these tests was evaluated in a 2012 study that tested samples from 150 individuals known to have HS [
         <a href="#rid147">
          147
         </a>
         ]. Test sensitivities were as follows:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         AGLT – 95 percent
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         EMA binding – 93 percent
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Pink test – 91 percent
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Osmotic fragility, incubated – 81 percent
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Osmotic fragility, fresh – 68 percent
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         GLT – 61 percent
        </p>
        <p>
        </p>
        <p>
         Combined testing with EMA binding and AGLT had a sensitivity of 100 percent; combined testing with EMA binding and pink test had a sensitivity of 99 percent; and EMA binding plus osmotic fragility (incubated or fresh) had a sensitivity of 95 percent [
         <a href="#rid147">
          147
         </a>
         ].
        </p>
        <p>
         Direct comparison of EMA testing versus OGE identified the benefits of EMA testing as a fast, widely available screening test for HS but also indicated the advantage of OGE to differentiate HS from other RBC membrane disorders [
         <a href="#rid156">
          156
         </a>
         ]. When the question is the differentiation between xerocytosis and spherocytosis, before proceeding to splenectomy, OGE as well as genetic evaluation for the pathogenic gene variant is preferable [
         <a href="#rid2">
          2,81,156
         </a>
         ].
        </p>
        <p>
         These results demonstrate that no single phenotypic testing has 100 percent sensitivity and specificity to accurately identify all individuals with HS, especially if the patient has been recently transfused. Test results should be compared with results of a normal control of similar age, evaluated in parallel with the patient's specimen, as well as with the reference range for many normal samples evaluated by the specific laboratory. Diagnostic yield may be improved by using two tests and by taking into account the personal and family history of the patient and evaluating the blood smear and RBC indices.
        </p>
        <p>
         These tests can also be positive in other conditions, and the results cannot be interpreted in isolation. If a positive test is not consistent with the clinical picture or findings on the peripheral blood smear, laboratory personnel or a consulting hematologist with expertise in interpreting these tests should be consulted [
         <a href="#rid118">
          118
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2584322989">
         <span class="h2">
          Specialized testing for selected cases (including genetic testing)
         </span>
         <span class="headingEndMark">
          —
         </span>
         In certain atypical cases in which further characterization of the RBC cytoskeletal/membrane proteins is needed, research-based gel electrophoresis can be done using RBC ghosts.
        </p>
        <p>
         Clinical grade next generation DNA sequencing is available by several academic and commercial laboratories to evaluate for the genetic cause of an RBC membranopathy or more broadly of a hereditary hemolytic anemia. Identifying a familial disease variant may be useful for prognosis and genetic counseling. (See
         <a class="local">
          'Testing relatives; reproductive testing and counseling'
         </a>
         below.)
        </p>
        <p>
         More importantly, misdiagnosis of hereditary xerocytosis (HX) as spherocytosis has to be avoided, since splenectomy is contraindicated in HX especially, because it predisposes patients to life-threatening venous and arterial thromboembolic complications, and it does not improve hemolysis either [
         <a href="#rid165">
          165-167
         </a>
         ].
        </p>
        <p>
         Resources for genetic testing are listed on the
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fgtr%2Fall%2Ftests%2F%3Fterm%3Dhereditary%2Bspherocytosis&amp;token=LvjFCZ8cn1hiWeAIf6mbn0OwQ%2BuUOpedf9SVvkoakWBfNLZwaIDHRqHO%2F1tc0YqwXfXdzHnl9nkoPB6miTS%2FQ1awXq%2BSEhVioz6VssvRksE%3D&amp;TOPIC_ID=7079" target="_blank">
          Genetic Testing Registry
         </a>
         website.
        </p>
        <p>
         Certain academic laboratories have a special interest or ability in performing this testing and may be contacted for further discussions. As examples:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Cincinnati Children's Molecular Genetics Laboratory:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Website –
         <a class="external" href="/external-redirect?target_url=http%3A%2F%2Fwww.cincinnatichildrens.org%2Fservice%2Fd%2Fdiagnostic-labs%2Fmolecular-genetics%2Fdefault%2F&amp;token=n3fx4sTcbs22kLBK2FMjFSNiBXFIAXwOlvFDHxNBoczzz%2FWKd9OiJe7pPTNo94udzLkJCp%2BAykenIcjDAMvo3Axzcseglo7UF3yTaLRW5OWvALUkLBSw0hah5bEtTSir&amp;TOPIC_ID=7079" target="_blank">
          www.cincinnatichildrens.org/moleculargenetics
         </a>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Phone – (513) 636-4474
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Blood Disease Reference Laboratory Program at Yale University:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Website –
         <a class="external" href="/external-redirect?target_url=http%3A%2F%2Fwww.medicine.yale.edu%2Fpathology%2Fclinical%2Fmdx%2F&amp;token=0HUifQW88zoSoaqQhS65op6pOir8qUrP6QOPzUCx%2BQV4ZrADWTRI%2Bt2qYyCe7FFS8OMaLAUteZXudpANiDpeaA%3D%3D&amp;TOPIC_ID=7079" target="_blank">
          www.medicine.yale.edu/pathology/clinical/mdx/
         </a>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Phone – (203) 737-1349
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Mayo Medical Laboratories:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Website –
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.mayomedicallaboratories.com%2Fcustomer-service%2Fcontacts.html&amp;token=NIRe5e5YXQR2YtIYkAdxz%2Bc1JChUjjGNo7kBAgRh9tYwaddHu3Wl1hmLgjmxPV%2Ft0LHEgJnIDcdf3DfAOouNEKBIH%2BTdcGEBGYoeHEt64Hg%3D&amp;TOPIC_ID=7079" target="_blank">
          https://www.mayomedicallaboratories.com/customer-service/contacts.html
         </a>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Phone – (800) 533-1710
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Email –
         <a class="__cf_email__" data-cfemail="d6bbbbba96bbb7afb9f8b3b2a3" href="/cdn-cgi/l/email-protection">
          [email protected]
         </a>
         (United States) or
         <a class="__cf_email__" data-cfemail="731e1f1a1a1d071f331e120a1c5d161706" href="/cdn-cgi/l/email-protection">
          [email protected]
         </a>
         (international)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3487876878">
         <span class="h2">
          Diagnosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         The diagnosis of HS is made in an individual who presents with DAT-negative hemolysis, an increased MCHC, a positive family history for HS, and/or spherocytes on the peripheral blood smear, by finding a positive result from one or more confirmatory tests such as EMA binding, osmotic fragility, or osmotic gradient ektacytometry (OGE). Specialized testing is especially important if splenectomy is being considered. Specialized testing may be omitted if definitive diagnosis is unlikely to alter management (eg, if hemolysis is mild and childbearing is not planned) or in resource-limited areas of the world [
         <a href="#rid118">
          118
         </a>
         ]. (See
         <a class="local">
          'Confirmatory tests'
         </a>
         above.)
        </p>
        <p>
         For an individual with a strong suspicion of HS and negative or equivocal testing by EMA binding, for whom accurate diagnosis was especially important (eg, due to a previous affected child), positive results from genetic testing are confirmatory for HS. Genetic testing is available in several specialized laboratories. (See
         <a class="local">
          'Specialized testing for selected cases (including genetic testing)'
         </a>
         above.)
        </p>
        <p>
         This testing is similar to that described in published guidelines [
         <a href="#rid118">
          118,141
         </a>
         ]. However, we are more likely to order confirmatory testing in all patients except those in resource-limited settings or those who do not have access to specialized testing for other reasons, as treatment for HS may differ from other conditions (eg, splenectomy is often used in HS but should be avoided in hereditary stomatocytosis). (See
         <a class="local">
          'Splenectomy'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H15480232">
         <span class="h2">
          Differential diagnosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         The differential diagnosis of HS includes a number of other hemolytic anemias with spherocytes on the peripheral blood smear:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Other inherited hemolytic anemias
         </strong>
         – Other inherited RBC membrane disorders include hereditary elliptocytosis (HE)  (
         <a class="graphic graphic_picture graphicRef95382" href="/z/d/graphic/95382.html" rel="external">
          picture 3
         </a>
         ) and elliptocytosis variants (hereditary pyropoikilocytosis [HPP])  (
         <a class="graphic graphic_picture graphicRef95383" href="/z/d/graphic/95383.html" rel="external">
          picture 4
         </a>
         ), overhydrated and dehydrated hereditary stomatocytosis (OHSt and DHSt respectively); DHSt is also known as hereditary xerocytosis (HX)  (
         <a class="graphic graphic_figure graphicRef117376" href="/z/d/graphic/117376.html" rel="external">
          figure 5
         </a>
         ). RBC enzyme disorders include glucose-6-phosphate dehydrogenase (G6PD) deficiency, pyruvate kinase (PK) deficiency, and other rarer metabolic disorders.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Like HS, these present with variable degrees of anemia and hemolysis and can be diagnosed at any age. Unlike the other disorders, G6PD deficiency (except for the disease due to rare class I variants) typically presents with episodes of hemolytic crisis after exposure to oxidant drugs rather than chronic hemolysis. Unlike the other membrane disorders, which each have distinctive morphologies on the blood smear, and the enzyme disorders, which typically have nonspecific findings (eg, mild reticulocytosis), HS is characterized by spherocytosis as the predominant morphology. (See
         <a class="medical medical_review" href="/z/d/html/5932.html" rel="external">
          "Overview of hemolytic anemias in children", section on 'Intrinsic hemolytic anemias'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7076.html" rel="external">
          "Diagnosis of hemolytic anemia in adults", section on 'Intracorpuscular'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         It is especially important to distinguish between HS and HSt because HS is generally helped by splenectomy, whereas in HSt, splenectomy should be avoided because it predisposes patients to life-threatening venous and arterial thromboembolic complications, and it does not improve hemolysis either [
         <a href="#rid165">
          165-167
         </a>
         ]. (See
         <a class="local">
          'Decision to pursue splenectomy'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Neonatal alloimmune hemolytic anemia
         </strong>
         –
         <strong>
         </strong>
         Neonatal alloimmune hemolytic anemia,
         <strong>
         </strong>
         historically known as hemolytic disease of the fetus and newborn (HDFN), is most frequently caused by ABO or Rh incompatibility between fetal RBCs and the mother's immune system; maternal antibodies cross the placenta and recognize the foreign (to the mother) fetal RBC antigens, leading to alloimmune hemolysis. Neonates may present with severe jaundice and anemia requiring aggressive treatment, and like in HS, HDFN can be associated with abundant spherocytes on the blood smear. Unlike HS, HDFN is a transient condition that resolves after the maternal antibodies are cleared, and HDFN is characterized by positive DAT testing, detecting the maternal alloantibodies on fetal RBCs, and demonstrating an immunologically significant discordance between maternal and neonatal blood type. (See
         <a class="medical medical_review" href="/z/d/html/5933.html" rel="external">
          "Alloimmune hemolytic disease of the newborn: Postnatal diagnosis and management"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Infantile pyknocytosis
         </strong>
         – Infantile pyknocytosis is a disorder of unknown etiology in which RBCs become hyperdense and dehydrated [
         <a href="#rid168">
          168
         </a>
         ]. Like HS, this condition presents in neonates with anemia and an increased mean corpuscular hemoglobin concentration (MCHC). Unlike HS, the RBCs have irregular borders and varying numbers of projections, and the condition resolves spontaneously during the first year of life (typically, three to nine months after birth) with no other intervention than supportive care (such as treatment of neonatal jaundice with phototherapy and PRBC transfusions as needed).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Congenital dyserythropoietic anemia (CDA)
         </strong>
         – CDA type II is an autosomal recessive rare hereditary anemia caused by biallelic
         <em>
          SEC23B
         </em>
         pathogenic variants.
         <em>
          SEC23B
         </em>
         encodes a member of the cytoplasmic coat protein II (COPII) complex, which is implicated in intracellular vesicle trafficking in eukaryotic cells, and loss of its function disturbs erythropoiesis. Like HS, some individuals may have significant hemolysis and/or splenomegaly, and like HS, some specialized tests such as EMA binding and OGE may be positive; this is because glycosylation and appropriate positioning of band 3 in the RBC cytoskeleton is compromised [
         <a href="#rid169">
          169
         </a>
         ]. Unlike HS, individuals with CDA-II have the characteristic finding of binucleate and multinucleate erythroblasts in the bone marrow, and the reticulocyte count is typically lower, indicating ineffective erythropoiesis, which in severe phenotypes tend to be associated with significant iron overload, disproportionate to the history of RBC transfusions [
         <a href="#rid118">
          118
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/5931.html" rel="external">
          "Overview of causes of anemia in children due to decreased red blood cell production", section on 'Congenital dyserythropoietic anemia'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Autoimmune hemolytic anemia (AIHA)
         </strong>
         – AIHA is caused by increased RBC destruction (hemolysis) triggered by autoantibodies directed against self-RBC antigens, with or without complement activation. It is a rare disease with an incidence of 1 to 3 per 100,000 people per year [
         <a href="#rid139">
          139
         </a>
         ]. Warm AIHA associated with an underlying disorder such as systemic lupus erythematosus (SLE) or without an underlying disorder is more common than cold AIHA, which is typically triggered by an infection such as infectious mononucleosis. Like HS, patients can have anemia and/or hemolysis of variable severity and abundant spherocytes on the peripheral blood smear. Unlike HS, in AIHA, DAT is typically positive, the family history is negative for hemolytic anemia, and prior complete blood counts (CBCs) will show a normal hemoglobin level and reticulocyte count. (See
         <a class="medical medical_review" href="/z/d/html/5934.html" rel="external">
          "Autoimmune hemolytic anemia (AIHA) in children: Classification, clinical features, and diagnosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7078.html" rel="external">
          "Warm autoimmune hemolytic anemia (AIHA) in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7084.html" rel="external">
          "Cold agglutinin disease"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H9">
         <span class="h1">
          MANAGEMENT
         </span>
        </p>
        <p class="headingAnchor" id="H15480821">
         <span class="h2">
          Overview of treatment
         </span>
         <span class="headingEndMark">
          —
         </span>
         As with most inherited hemolytic anemias, treatment is directed at preventing or minimizing complications of chronic hemolysis and anemia. There are no specific treatments directed at the underlying red blood cell (RBC) membrane abnormality.
        </p>
        <p class="headingAnchor" id="H3317594383">
         <span class="h3">
          Monitoring
         </span>
         <span class="headingEndMark">
          —
         </span>
         The frequency of patient monitoring depends on disease severity and symptoms. (See
         <a class="local">
          'Disease severity and age of presentation'
         </a>
         above.)
        </p>
        <p>
         Babies born to families with history of HS need careful monitoring for hyperbilirubinemia rising already within the first day of life. Anemia ensues typically two to three weeks after birth as the normal neonatal hyposplenism resolves, and hemoglobin frequently decreases enough to require transfusion [
         <a href="#rid2">
          2,119
         </a>
         ].
        </p>
        <p>
         Once a baseline has been established, an annual visit is sufficient for a child with mild hemolysis, with closer monitoring during viral or other infections that might cause more severe anemia [
         <a href="#rid118">
          118
         </a>
         ]. Growth should be monitored, and patients and/or families should be informed about the possible risk of transient aplastic crisis, including the symptoms and the need to seek medical attention. Adults with mild disease may receive routine medical and preventive care; those with more severe hemolysis may require more frequent monitoring, with the interval depending on their specific needs. (See
         <a class="local">
          'Hemolytic anemia'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H3692396082">
         <span class="h3">
          Supportive measures
         </span>
         <span class="headingEndMark">
          —
         </span>
         General supportive measures may include the following, depending on disease severity:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Treatment of hyperbilirubinemia
         </strong>
         – If a neonate is suspected of having HS (eg, based on positive family history and neonatal jaundice), supportive treatment should be initiated for the neonatal hyperbilirubinemia and/or anemia without awaiting diagnostic confirmation. Therapy for hyperbilirubinemia may range from simple phototherapy to exchange transfusion [
         <a href="#rid119">
          119
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/5063.html" rel="external">
          "Unconjugated hyperbilirubinemia in term and late preterm newborns: Initial management"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Folic acid
         </strong>
         –
         <a class="drug drug_general" data-topicid="8475" href="/z/d/drug information/8475.html" rel="external">
          Folic acid
         </a>
         supplementation is appropriate for those with moderate to severe hemolysis and/or during pregnancy. This is based on an increased requirement for folate in RBC production. There are no clinical trials investigating the role of folic acid treatment. However, observational studies that documented megaloblastic anemia in a small number of patients with HS were performed before the institution of routine folic acid supplementation of grains and cereals [
         <a href="#rid98">
          98
         </a>
         ]. This, coupled with the low cost and minimal toxicity of folic acid, make it an attractive and simple therapy to recommend.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The typical dose for infants up to 6 to 12 months of age is 0.4 mg daily, while thereafter 1 mg/day is typically prescribed for those with moderate to severe hemolysis. Individuals with HS of any severity who are planning to be pregnant and during pregnancy should receive a dose of 2 to 4 mg/day. (See
         <a class="medical medical_review" href="/z/d/html/423.html" rel="external">
          "Preconception and prenatal folic acid supplementation"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         For individuals with mild hemolysis who have normal intake of fresh fruits and vegetables (or folic-acid-supplemented grains), daily
         <a class="drug drug_general" data-topicid="8475" href="/z/d/drug information/8475.html" rel="external">
          folic acid
         </a>
         is not required, but for those who place a high value on avoiding folate deficiency, which could cause worsening anemia, taking daily folic acid (on the typical dose of 1 mg daily) is safe and inexpensive, and there are essentially no side effects or contraindications.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Erythropoietin
         </strong>
         – Erythropoietin (Epo) may be helpful in reducing the need for transfusion in some infants [
         <a href="#rid118">
          118,122
         </a>
         ]. Typically, this can be discontinued around the age of nine months. In one study, the use of recombinant human Epo (1000 international units/kg per week) with iron supplementation obviated the need for transfusion in 13 of 16 infants with HS and severe anemia due to inadequate reticulocytosis during the first months of life [
         <a href="#rid122">
          122
         </a>
         ]. As the infants grew and began to mount an adequate erythropoietic response, the Epo dose could be tapered and discontinued before the age of nine months.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Considerations related to splenomegaly
         </strong>
         – There are no special restrictions (eg, no activity limitations) on children with splenomegaly due to HS [
         <a href="#rid118">
          118
         </a>
         ]. However, those with an unusually large spleen should be made aware of the risk of splenic rupture during contact sports. (See
         <a class="medical medical_review" href="/z/d/html/7134.html" rel="external">
          "Splenomegaly and other splenic disorders in adults", section on 'Sports participation and fall risk'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H4248207474">
         <span class="h2">
          Transfusions
         </span>
         <span class="headingEndMark">
          —
         </span>
         Blood transfusion is often required in infancy, even in mild autosomal dominant HS. The transfusion requirement in the first months of life does not necessarily predict a severe phenotype. Transfusions may be needed in older children and adults in other settings (eg, aplastic or hemolytic crisis with infections, pregnancy). Typical hemoglobin thresholds for transfusion depend on the age of the patient, symptoms, and comorbidities.
        </p>
        <p>
         In autosomal dominant HS and in most cases of autosomal recessive
         <em>
          EPB42
         </em>
         -associated HS, transfusions usually are not required on a chronic basis or for a long enough time to cause iron overload. In contrast, most patients with autosomal recessive
         <em>
          SPTA1
         </em>
         -associated HS are transfusion-dependent until splenectomy is performed (if appropriate). (See
         <a class="local">
          'Splenectomy'
         </a>
         below.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Infants
         </strong>
         – Many infants may require transfusions for anemia, and some may need exchange transfusion for rapidly increasing hyperbilirubinemia. Older children with autosomal dominant HS of mild or moderate severity may tolerate a hemoglobin as low as 7 g/dL without transfusion if reticulocyte count is increasing and this is a temporary anemia exacerbation. However, chronic anemia with Hgb &lt;7 g/dL is typically due to severe autosomal recessive HS caused by
         <em>
          SPTA1
         </em>
         (or more rarely
         <em>
          ANK1
         </em>
         biallelic variants); inadequate transfusion and chronic anemia in those cases is frequently associated with growth delay and iron overload due to ineffective erythropoiesis. (See
         <a class="medical medical_review" href="/z/d/html/5910.html" rel="external">
          "Red blood cell transfusion in infants and children: Indications"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Adults
         </strong>
         – Adults may require transfusions for anemia, with thresholds determined by their clinical status, as discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/7948.html" rel="external">
          "Indications and hemoglobin thresholds for RBC transfusion in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Aplastic crisis
         </strong>
         – Individuals with an aplastic crisis due to parvovirus infection or other bone marrow insult may require transfusions if they have a decreasing hemoglobin level without a robust reticulocytosis. The usual course of parvovirus-associated anemia is spontaneous resolution within a few days or weeks. Infected individuals are monitored with twice-weekly complete blood counts (CBCs) and reticulocyte counts to determine the expected hemoglobin nadir and the need for transfusion. (See
         <a class="medical medical_review" href="/z/d/html/8330.html" rel="external">
          "Treatment and prevention of parvovirus B19 infection", section on 'Transient aplastic crisis'
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         Consideration of transfusional iron overload typically occurs after transfusion of &gt;15 to 20 units of RBCs (&gt;10 units in smaller children). Adults with mild hemolysis may have a slight increase in iron absorption, and if this occurs in the setting of hereditary hemochromatosis, which is common, iron overload may occur. Screening for iron overload, management, and related subjects are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/7157.html" rel="external">
          "Approach to the patient with suspected iron overload", section on 'Transfusional iron overload'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H10">
         <span class="h2">
          Splenectomy
         </span>
        </p>
        <p class="headingAnchor" id="H1295833058">
         <span class="h3">
          Decision to pursue splenectomy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Decisions regarding splenectomy must take into account the severity of hemolysis, age of the patient, and the potential perioperative and post-splenectomy long-term complications [
         <a href="#rid118">
          118,136,165
         </a>
         ]. For those with relatively severe hemolysis, splenectomy is effective at improving anemia.
        </p>
        <p>
         Other considerations include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Diagnostic confirmation
         </strong>
         – It is important to confirm that the diagnosis is HS rather than another inherited hemolytic anemia such as hereditary stomatocytosis (HSt), for which splenectomy is neither safe nor effective. (See
         <a class="local">
          'Differential diagnosis'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/7068.html" rel="external">
          "Hereditary stomatocytosis (HSt) and hereditary xerocytosis (HX)", section on 'Management'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Type of HS (genotype)
         </strong>
         – Patients with
         <em>
          SPTA1
         </em>
         -associated autosomal recessive HS with the most common genotype of a null
         <em>
          SPTA1
         </em>
         variant in trans to the Low Expression PRAgue (alpha-LEPRA) allele c.4339-99C&gt;T are expected to have transfusion-dependent severe HS that will respond well to splenectomy [
         <a href="#rid35">
          35,79,80
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The use of splenectomy in individuals with moderate disease is individualized. We are more likely to advise splenectomy for individuals with more severe hemolysis and/or greater symptoms (eg, abdominal symptoms related to splenomegaly, distress related to jaundice) or for those with growth delays or skeletal changes related to extramedullary hematopoiesis.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In contrast, the most severe cases with HS due to complete alpha-spectrin or band 3 deficiency do not respond to splenectomy, and they require either lifelong chronic transfusions and chelation or hematopoietic stem cell transplantation (HSCT). (See
         <a class="local">
          'Beta spectrin or alpha-spectrin deficiency due to SPTB or SPTA1 pathogenic variants'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         For children with HS who remain transfusion-dependent after one year of age, we recommend that genetic diagnosis should be pursued to understand the cause and prognosis and assist with management decisions. Genetic evaluation before planning for splenectomy will also assist to avoid misdiagnosis of hereditary xerocytosis, for which splenectomy will not be safe or effective. (See
         <a class="local">
          'Specialized testing for selected cases (including genetic testing)'
         </a>
         above and
         <a class="local">
          'Differential diagnosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Autosomal dominant forms of HS generally are not transfusion-dependent after infancy. If the genotype is that of one of the forms of autosomal dominant HS, further evaluation needs to be performed to investigate for comorbidities that would make an autosomal dominant HS present as a transfusion-dependent disease after infancy. (See
         <a class="local">
          'Inheritance patterns'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Ideal age
         </strong>
         – Ideally, splenectomy is delayed until the individual is &gt;5 years of age to reduce the likelihood of sepsis due to absent splenic function [
         <a href="#rid118">
          118
         </a>
         ]. It is better to plan for a total splenectomy after the age of five years and after completing the pre-splenectomy immunizations for encapsulated bacteria at that age when the spleen is considered mature enough to mount an optimal response to those immunizations.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Until the age of five years, the patient would likely benefit from a plan for chronic transfusions to avoid growth delay and decrease stress erythropoiesis; monitoring for iron overload and appropriate chelation treatment are used to avoid exacerbation of growth delay by iron overload [
         <a href="#rid170">
          170
         </a>
         ]. (See
         <a class="local">
          'Transfusions'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Partial versus total splenectomy
         </strong>
         – In children younger than five years of age for whom chelation is not successful, or if the family/caregivers prefer to avoid chronic transfusions, consideration may be given to partial splenectomy after three years of age. All of the appropriate pre-splenectomy immunizations should be completed prior to partial splenectomy, with the plan to repeat them after five years of age, in case of suboptimal response. A successful partial splenectomy reduces the risk of sepsis from encapsulated bacteria compared to total splenectomy, and in some patients, partial splenectomy may serve as a long-term treatment, even for autosomal recessive HS. (See
         <a class="local">
          'Operative techniques'
         </a>
         below and
         <a class="medical medical_review" href="/z/d/html/117640.html" rel="external">
          "Elective (diagnostic or therapeutic) splenectomy", section on 'Partial splenectomy'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Gallstone disease
         </strong>
         – Individuals with symptomatic gallstone disease who require cholecystectomy should be evaluated for the possible role of simultaneous splenectomy, but this should only be pursued if clinically indicated (eg, symptomatic hemolytic anemia and/or severe complications of hemolysis). Simultaneous cholecystectomy can be performed if gallstones are also present. (See
         <a class="local">
          'Pigment gallstones'
         </a>
         above and
         <a class="local">
          'Gallstones'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Some individuals with mild hemolysis may pursue splenectomy as a means of reducing gallstone formation, but for most individuals, the risks of splenectomy exceed the possible benefit [
         <a href="#rid171">
          171
         </a>
         ]. (See
         <a class="local">
          'Complications'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Splenic embolization
         </strong>
         – In patients for whom splenectomy is appropriate but surgery is refused or contraindicated, partial splenic embolization has been employed, with anecdotal reports of success [
         <a href="#rid172">
          172
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         Our approach is consistent with a 2011 guideline from the British Committee for Standards in Haematology (BCSH) and a 2017 guideline from the European Hematology Association (EHA) [
         <a href="#rid118">
          118,165
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H263114706">
         <span class="h3">
          Supporting evidence for splenectomy
         </span>
         <span class="headingEndMark">
          —
         </span>
         There are no randomized trials comparing splenectomy with expectant management. Observational evidence to support the efficacy of both total and partial splenectomy includes the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A 2016 series followed 79 individuals with HS after undergoing partial splenectomy at a single institution in France [
         <a href="#rid173">
          173
         </a>
         ]. The indications for splenectomy were transfusion dependence or severe anemia in 39 and other symptoms (fatigue, gallstones, icterus) in 40. The mean age for splenectomy was 4.3 years for those who were transfusion-dependent and 11 years for those with symptoms of anemia. The procedure involved removal of 85 to 95 percent of splenic tissue using an open approach, with concurrent cholecystectomy if gallstones were present.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         At a mean of 11 years of follow-up, all patients but one had a significant improvement in hemoglobin level (mean increase, 0.97 g/dL) and reduction in number of transfusions (from 3.1 to 0.2 per patient per year), a benefit that remained stable or continued to improve over the course of 10 years. A composite endpoint of no symptoms from anemia was documented in 69 of the children (87 percent) and 65 were transfusion-free.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Regrowth of the splenic remnant was common, and 21 patients (27 percent) underwent reoperation with total splenectomy, 49 percent for a significant decrease in hemoglobin and 51 percent for other symptoms related to splenomegaly or hemolysis. The typical interval between the initial partial splenectomy and the subsequent total splenectomy was seven to nine years. Of the 46 who did not undergo concomitant cholecystectomy, 16 (35 percent) developed gallstones, typically several years after splenectomy. There were no severe infections requiring hospitalization and no thrombotic complications.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Two reports from 2015 and 2016 described outcomes in a consortium registry of patients with a variety of congenital hemolytic anemias (Splenectomy in Congenital Hemolytic Anemia [SICHA]) that included 61 children and adolescents with HS [
         <a href="#rid174">
          174,175
         </a>
         ]. Procedures were evenly divided between total and partial splenectomy; most were performed laparoscopically. Hemoglobin increased in all of the children with HS (mean increase, 4.1 g/dL; greater increases with total than partial splenectomy), and transfusion dependence in the group as a whole decreased from 22 to 4 percent [
         <a href="#rid175">
          175
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A 2001 series of 48 individuals with HS reported that those who had undergone splenectomy had a mean hemoglobin of approximately 15 g/dL, and those who had not undergone splenectomy had a mean hemoglobin of approximately 12 g/dL  (
         <a class="graphic graphic_table graphicRef54945" href="/z/d/graphic/54945.html" rel="external">
          table 2
         </a>
         ) [
         <a href="#rid99">
          99
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         Additional smaller series have reported similar findings, although some have observed more concerning complications such as post-splenectomy sepsis [
         <a href="#rid176">
          176-181
         </a>
         ]. (See
         <a class="local">
          'Complications'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H721792272">
         <span class="h3">
          Pre-splenectomy considerations
         </span>
        </p>
        <p class="headingAnchor" id="H4145667530">
         <span class="h4">
          Immunizations
         </span>
         <span class="headingEndMark">
          —
         </span>
         For individuals considering splenectomy (total or partial), it is prudent to ensure that all immunizations for encapsulated organisms have been administered with sufficient time to develop an antibody response (typically approximately two weeks before the surgery). Specific recommendations vary based on patient age and number of vaccine doses previously received.
        </p>
        <p>
         Details of specific vaccines are summarized in the tables for children  (
         <a class="graphic graphic_table graphicRef119182" href="/z/d/graphic/119182.html" rel="external">
          table 3
         </a>
         ) and adults  (
         <a class="graphic graphic_table graphicRef119180" href="/z/d/graphic/119180.html" rel="external">
          table 4
         </a>
         ) and discussed in separate topic reviews. (See
         <a class="medical medical_review" href="/z/d/html/1412.html" rel="external">
          "Prevention of infection in patients with impaired splenic function", section on 'Vaccinations'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1412.html" rel="external">
          "Prevention of infection in patients with impaired splenic function", section on 'Children'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/117640.html" rel="external">
          "Elective (diagnostic or therapeutic) splenectomy", section on 'Vaccinations'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2752299165">
         <span class="h4">
          Gallstones
         </span>
         <span class="headingEndMark">
          —
         </span>
         For individuals with gallstones, it may be advantageous to perform simultaneous cholecystectomy at the time of splenectomy. This decision takes into account the size and symptoms of the stones as well as other operative factors. The use of cholecystectomy in individuals with asymptomatic gallstones is controversial; patient values and preferences as well as comorbidities and risks of complications such as cholangitis and acute biliary pancreatitis in a patient with chronic hemolytic anemia and pigment gallstones should be factored into this decision [
         <a href="#rid182">
          182
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/673.html" rel="external">
          "Approach to the management of gallstones"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H15480814">
         <span class="h3">
          Operative techniques
         </span>
         <span class="headingEndMark">
          —
         </span>
         Splenectomy was traditionally performed as a total splenectomy via laparotomy, which allows a search to be made for accessory splenic tissue, which may be located at other sites within the abdomen. If not removed, an accessory spleen may grow and result in the recurrence of symptomatic anemia [
         <a href="#rid183">
          183
         </a>
         ].
        </p>
        <p>
         However, laparoscopic splenectomy is increasingly used by surgeons with expertise in this technique. There are no randomized trials comparing open versus laparoscopic splenectomy in HS; however, observational studies in broader pediatric populations and case series have observed that, when performed properly, laparoscopic splenectomy is associated with lower complication rates and shorter hospital stays [
         <a href="#rid184">
          184-189
         </a>
         ]. Laparoscopic splenectomy appears to be equally effective in locating and removing an accessory spleen if present [
         <a href="#rid187">
          187
         </a>
         ]. Thus, laparoscopic splenectomy is used when there is appropriate institutional and surgical expertise [
         <a href="#rid118">
          118,190
         </a>
         ]. In rare cases with a very large spleen, it may be necessary to extend the incision. (See
         <a class="medical medical_review" href="/z/d/html/117640.html" rel="external">
          "Elective (diagnostic or therapeutic) splenectomy", section on 'Surgical approach'
         </a>
         .)
        </p>
        <p>
         For younger children who cannot delay splenectomy until after five years of age, we suggest partial splenectomy (also called subtotal or near-total splenectomy). There are no randomized trials comparing partial splenectomy with total splenectomy in HS, and the decision between total and partial splenectomy is made on a case-by-case basis. Compared with total splenectomy, partial splenectomy is likely to be effective in reducing hemolysis while maintaining splenic immune function, although it is probably less effective than total splenectomy in reducing hemolysis [
         <a href="#rid176">
          176,177,191-200
         </a>
         ].
        </p>
        <p>
         Following partial splenectomy, the spleen eventually regrows and regains part or all of its previous size, and a second (complete) splenectomy may be required. In many cases, this is performed at a time when the patient is considerably older, with a reduced risk of sepsis. Some individuals who undergo near-total splenectomy may have less regrowth of the splenic remnant [
         <a href="#rid194">
          194
         </a>
         ].
        </p>
        <p>
         Partial/subtotal splenectomy should be accompanied by all of the precautions regarding potential sepsis risk (eg, vaccinations, prophylactic antibiotics for at least a year postoperatively and until residual splenic function can be determined) in case of secondary necrosis of the splenic remnant [
         <a href="#rid191">
          191
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3216292777">
         <span class="h3">
          Post-splenectomy course
         </span>
         <span class="headingEndMark">
          —
         </span>
         In our experience, the typical post-splenectomy course includes an increase in hemoglobin, a decrease in reticulocyte count, and a decrease in serum bilirubin levels, all of which occur over the course of several days. Often, the hemoglobin and bilirubin become normal or near normal, although RBC survival remains shorter than normal and the reticulocyte count may remain mildly elevated.
        </p>
        <p>
         In individuals with severe disease due to the common form of
         <em>
          SPTA1
         </em>
         -associated autosomal recessive HS, the risk of life-threatening anemia and the need for regular transfusions is eliminated, with the hemoglobin reaching normal and sometimes high normal levels with total splenectomy; with partial splenectomy some degree of anemia may persist; adverse effects on growth and development and pain due to splenomegaly will also be ameliorated.
        </p>
        <p>
         This is consistent with observations published by other experts [
         <a href="#rid118">
          118,136,165,201
         </a>
         ].
        </p>
        <p>
         The likelihood of requiring cholecystectomy for gallstone disease may also be reduced, as noted above; however, reducing the need for cholecystectomy should not be the sole indication for splenectomy. (See
         <a class="local">
          'Decision to pursue splenectomy'
         </a>
         above.)
        </p>
        <p>
         Patients with the most severe form of HS (near-fatal hydrops fetalis) with complete alpha-spectrin or band 3 deficiency (due to biallelic null variants in
         <em>
          SPTA1
         </em>
         or
         <em>
          SLC4A1
         </em>
         , respectively) do not experience improvement with splenectomy. These patients have required in utero transfusions to reach term delivery, or they were born prematurely and had RBC transfusion support early in the neonatal period. They tend to have a characteristic reticulocytopenia even with significant anemia. These patients can be managed with chronic transfusions and chelation, similarly to thalassemia major patients, or with HSCT [
         <a href="#rid35">
          35,81
         </a>
         ]. (See
         <a class="local">
          'Beta spectrin or alpha-spectrin deficiency due to SPTB or SPTA1 pathogenic variants'
         </a>
         above and
         <a class="local">
          'Transfusions'
         </a>
         above and
         <a class="local">
          'Hematopoietic stem cell transplantation'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H12">
         <span class="h3">
          Complications
         </span>
         <span class="headingEndMark">
          —
         </span>
         Splenectomy has a number of known risks of which patients (or parents/caregivers) should be aware [
         <a href="#rid165">
          165
         </a>
         ].
        </p>
        <p>
         General information about operative and postoperative risks is presented separately. (See
         <a class="medical medical_review" href="/z/d/html/117640.html" rel="external">
          "Elective (diagnostic or therapeutic) splenectomy", section on 'Postoperative risks'
         </a>
         .)
        </p>
        <p>
         Evidence regarding postoperative risks specific to HS includes:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Operative risks
         </strong>
         – Operative risks such as infection, bleeding, or injury to adjacent organs such as the stomach or tail of the pancreas; these are relatively infrequent.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Infections
         </strong>
         – Infections including overwhelming post-splenectomy infection (OPSI), from encapsulated organisms (eg,
         <em>
          Streptococcus pneumoniae, Neisseria meningitidis, H. influenzae
         </em>
         ) that can no longer be removed by normal splenic clearance mechanisms, as well as certain other microorganisms including plasmodia,
         <em>
          Babesia
         </em>
         ,
         <em>
          Bordetella
         </em>
         , and
         <em>
          Capnocytophaga
         </em>
         species (from animal bites) [
         <a href="#rid165">
          165
         </a>
         ]. These risks are thought to be highest in the first two to three years following splenectomy and in individuals undergoing splenectomy before five to six years of age, but they also remain elevated for life [
         <a href="#rid202">
          202
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         A 1973 review evaluated 850 patients, mostly infants and children, who had undergone splenectomy for HS; 3.5 percent developed sepsis and 2.2 percent died of infection [
         <a href="#rid203">
          203
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         A 1995 review evaluated 226 patients with HS who underwent splenectomy up to 45 years earlier [
         <a href="#rid204">
          204
         </a>
         ]. Four deaths from sepsis occurred 2, 18, 23, and 30 years after splenectomy, and the estimated mortality from overwhelming sepsis was 0.73 per 1000 patient-years. The mortality rates for the 35 children who underwent splenectomy prior to six years of age and for the 191 individuals who underwent splenectomy at an older age were 1.12 and 0.66 per 1000 years, respectively, both of which were far higher than those seen in the general population.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         A 1999 review of 264 children who underwent splenectomy at a single medical center reported that 10 (3.8 percent) developed post-splenectomy sepsis within a mean period of two years [
         <a href="#rid205">
          205
         </a>
         ]. Nine of the 10 episodes occurred in patients whose surgery was performed between the ages of zero and five years.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         However, risks of sepsis are likely to have declined with improved options for preoperative vaccinations and postoperative prophylactic penicillin. This was illustrated in a 1991 study from the Danish National Patient Registry that demonstrated a dramatic reduction in serious
         <em>
          S. pneumoniae
         </em>
         infections following pneumococcal vaccination [
         <a href="#rid206">
          206
         </a>
         ]. Individuals who did not receive appropriate pre-splenectomy vaccinations should have a thorough review of their immunization history and should receive vaccinations as discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/1412.html" rel="external">
          "Prevention of infection in patients with impaired splenic function"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          VTE
         </strong>
         – Venous thromboembolic (VTE) complications include thromboses of the deep veins, pulmonary emboli, splenic or portal vein thrombosis, as well as thrombosis in other unusual sites [
         <a href="#rid207">
          207,208
         </a>
         ]. VTE events appear to be more common in individuals with HS who undergo splenectomy than in those who do not, but the individuals who undergo splenectomy may have had more severe underlying disease, making direct comparisons difficult [
         <a href="#rid137">
          137
         </a>
         ]. Thromboprophylaxis at the time of surgery should be based on standard practices; there is no indication for extended thromboprophylaxis beyond the usual duration [
         <a href="#rid118">
          118
         </a>
         ]. This subject is discussed in detail separately:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Children – (See
         <a class="medical medical_review" href="/z/d/html/5916.html" rel="external">
          "Venous thrombosis and thromboembolism (VTE) in children: Treatment, prevention, and outcome", section on 'Approach to VTE prophylaxis'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Adults – (See
         <a class="medical medical_review" href="/z/d/html/1339.html" rel="external">
          "Prevention of venous thromboembolic disease in adult nonorthopedic surgical patients"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Arterial thrombosis
         </strong>
         – Arterial thrombotic events may also be increased relative to individuals with HS who do not undergo splenectomy, with the same caveat that applies to VTE (patients who undergo splenectomy may have more severe underlying disease) [
         <a href="#rid137">
          137,209
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Pulmonary hypertension
         </strong>
         – It is not clear whether pulmonary artery hypertension (PAH) is a complication of splenectomy in HS. A case report described an individual with HS who underwent splenectomy at the age of 15 years and then developed PAH 32 years later [
         <a href="#rid210">
          210
         </a>
         ]. Retrospective studies have suggested that individuals who have undergone splenectomy for HS and other hemolytic anemias are at greater risk of PAH than those who have not undergone splenectomy; however, it is not clear whether the increased risk is due to the underlying disorder, the splenectomy, or the combination [
         <a href="#rid166">
          166,211-214
         </a>
         ]. In some cases, affected individuals also had hypercoagulable states, potentially further confounding a possible association [
         <a href="#rid212">
          212,215
         </a>
         ]. If PAH occurs, it may take many years. In a study that evaluated 26 children with HS at a median of 4.5 years after splenectomy, none had evidence of PAH [
         <a href="#rid216">
          216
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Frequency of complications
         </strong>
         – In a 2009 administrative database review spanning the years 1988 to 2004 that included 1657 children and adolescents &lt;18 years with a diagnosis of HS who underwent total splenectomy at an age range of 5 to 12 years, no adverse event occurred in more than 1 percent of the cases during the hospitalization for surgery [
         <a href="#rid217">
          217
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2421354493">
         <span class="h2">
          Hematopoietic stem cell transplantation
         </span>
         <span class="headingEndMark">
          —
         </span>
         Allogeneic hematopoietic stem cell transplantation (HSCT) is not used in common cases of HS due to an unfavorable risk-benefit ratio; however, a case was reported in which an individual with both HS and chronic myelogenous leukemia (CML) underwent allogeneic HSCT, which cured both disorders [
         <a href="#rid218">
          218
         </a>
         ].
        </p>
        <p>
         HSCT may be appropriate in the rare cases of autosomal recessive HS due to complete alpha-spectrin or band 3 deficiency, presenting with near-fatal hydrops fetalis, requiring in utero transfusions, or salvaged by premature delivery and early initiation of RBC transfusions; this disease does not respond to splenectomy, and patients require either lifelong chronic transfusions with iron chelation or HSCT [
         <a href="#rid35">
          35
         </a>
         ]. (See
         <a class="local">
          'Beta spectrin or alpha-spectrin deficiency due to SPTB or SPTA1 pathogenic variants'
         </a>
         above and
         <a class="local">
          'Transfusions'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H5240189">
         <span class="h2">
          Testing relatives; reproductive testing and counseling
         </span>
         <span class="headingEndMark">
          —
         </span>
         If one child is born with HS, there may be concern about HS in a sibling. Thus, if HS is diagnosed in a child, we obtain a full family history and obtain a CBC, reticulocyte count, and examination of the peripheral blood smear on each parent and sibling in order to determine whether the spherocytic gene variant is dominant or recessive.
        </p>
        <p>
         It is especially important to test a newborn sibling for HS, as well as newborns of affected parents for HS (testing that may require additional confirmatory testing such as EMA binding, osmotic gradient ektacytometry, or targeted sequencing for a known familial variant causing HS), as this may be associated with severe degrees of hyperbilirubinemia and anemia during the neonatal period. (See
         <a class="local">
          'Confirmatory tests'
         </a>
         above.)
        </p>
        <p>
         Appropriate counseling can be performed once this information has been obtained. This may be done by a clinician with expertise in hemolytic anemias or by a genetic counselor. It is possible for an individual with no hemolysis, no spherocytes on the blood smear, and a normal reticulocyte count to be a carrier of HS, which may be relevant in certain kindreds [
         <a href="#rid118">
          118
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/103304.html" rel="external">
          "Genetic counseling: Family history interpretation and risk assessment"
         </a>
         .)
        </p>
        <p>
         For individuals of childbearing age with HS, review of the familial gene variant and its mode of transmission (autosomal dominant or recessive) may be useful for informing discussions of the likelihood of HS in children. If the familial variant is known to act in an autosomal dominant fashion, it is important to make this information clear in the prenatal record and to make the information available to the pediatrician before delivery in order to stress the importance of close monitoring for neonatal hyperbilirubinemia starting at the first day of life [
         <a href="#rid119">
          119
         </a>
         ]. Some individuals who had HS as a child and were treated with splenectomy may have forgotten about the condition or may not realize the implications for their child.
        </p>
        <p class="headingAnchor" id="H3400613587">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/111043.html" rel="external">
          "Society guideline links: Anemia in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H15480873">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Genetics and pathophysiology
         </strong>
         – Hereditary spherocytosis (HS) is a heterogeneous group of disorders caused by variants in certain genes that encode proteins of the red blood cell (RBC) membrane skeleton:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Spectrin (
         <em>
          SPTA1
         </em>
         and
         <em>
          SPTB
         </em>
         genes)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Ankyrin (
         <em>
          ANK1
         </em>
         gene)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Band 3 (
         <em>
          SLC4A1
         </em>
         gene)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Protein 4.2 (
         <em>
          EPB42
         </em>
         gene)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         These abnormalities decrease the levels of proteins that link the RBC inner membrane skeleton to the outer lipid bilayer  (
         <a class="graphic graphic_figure graphicRef79183" href="/z/d/graphic/79183.html" rel="external">
          figure 2
         </a>
         ), which in turn leads to membrane vesiculation, spherocyte formation, and hemolysis. Approximately three-fourths of these variants show autosomal dominant inheritance, 10 to 15 percent show autosomal recessive inheritance, and the remainder are de novo variants, most frequently
         <em>
          of ANK1
         </em>
         , causing new autosomal dominant disease. (See
         <a class="local">
          'Pathophysiology'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Prevalence
         </strong>
         – HS is seen in all populations but appears to be especially common in people of northern European ancestry, where it affects up to 1 in 2000 to 1 in 5000 (prevalence 0.02 to 0.05 percent). HS may account for as many as 1 percent of infants with neonatal jaundice. (See
         <a class="local">
          'Epidemiology'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical findings
         </strong>
         – HS can present at any age and with any severity. The majority of affected individuals have mild or moderate hemolytic anemia. Neonates with HS often have jaundice and hyperbilirubinemia; the serum bilirubin level may not peak until several days after birth, but it may increase rapidly, even on the first day of life. In older children and adults, HS may present as an incidental finding of hemolytic anemia or spherocytes on the blood smear  (
         <a class="graphic graphic_picture graphicRef70611" href="/z/d/graphic/70611.html" rel="external">
          picture 2
         </a>
         ), or the individual may be symptomatic from anemia, splenomegaly, or pigment gallstones. Exacerbations of anemia may occur with parvovirus infection, mononucleosis, or pregnancy. (See
         <a class="local">
          'Clinical presentation'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Evaluation
         </strong>
         – All individuals with suspected HS based on a known family history and/or clinical findings should have complete blood count (CBC) with reticulocyte count, evaluation of RBC indices, review of the blood smear by an experienced individual, testing for hemolysis, and direct antiglobulin testing (DAT; Coombs testing). In neonates or infants, a mean corpuscular hemoglobin concentration (MCHC) ≥36 g/dL is highly suggestive of HS. Spherocytes and reticulocytosis are less reliable indicators in infants but are important in older children and adults. (See
         <a class="local">
          'Initial testing'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Diagnostic confirmation
         </strong>
         – Several tests are available to confirm the diagnosis of HS (see
         <a class="local">
          'Diagnosis'
         </a>
         above):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          OF
         </strong>
         – Osmotic fragility is the traditional confirmatory test. (See
         <a class="local">
          'Confirmatory tests'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          EMA
         </strong>
         – EMA (eosin-5-maleimide) binding is a widely available and sensitive test requiring as little as 5 microL of blood. (See
         <a class="local">
          'Confirmatory tests'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Ektacytometry
         </strong>
         – Osmotic gradient ektacytometry is very sensitive and the most specific phenotypic test, especially in differentiating HS from other RBC membrane disorders; it requires at least 0.3 mL of blood. (See
         <a class="local">
          'Confirmatory tests'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          NGS
         </strong>
         – Next generation DNA sequencing (NGS) is helpful if the patient has been transfused and phenotypic testing of their RBCs is compromised with donor RBCs. Sequencing panels for RBC membrane disorders or hereditary hemolytic anemias are often used. NGS is also useful when deciding whether to pursue splenectomy and making other treatment decisions. (See
         <a class="local">
          'Specialized testing for selected cases (including genetic testing)'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Differential diagnosis
         </strong>
         – The differential diagnosis of HS includes other hemolytic anemias with spherocytes on the blood smear  (
         <a class="graphic graphic_figure graphicRef117376" href="/z/d/graphic/117376.html" rel="external">
          figure 5
         </a>
         ). Other inherited RBC membrane disorders include hereditary elliptocytosis (HE), hereditary stomatocytosis or xerocytosis syndromes (HSt or HX), and congenital dyserythropoietic anemia (CDA) type II. Other possible diagnoses in neonates include neonatal alloimmune hemolytic anemia and infantile pyknocytosis. Other possible diagnoses in children and adults include autoimmune or drug-induced hemolytic anemias. (See
         <a class="local">
          'Differential diagnosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Management
         </strong>
         – Treatment of HS is directed at minimizing complications of chronic hemolysis and anemia. (See
         <a class="local">
          'Management'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Monitoring and supportive care
         </strong>
         – Close monitoring is important for neonates, who may require phototherapy for hyperbilirubinemia, and, in severe cases, exchange transfusion. Even neonates with mild autosomal dominant HS may develop anemia severe enough to require RBC transfusion two to three weeks after birth. If the transfusion requirement persists after two to three months of age in these infants, erythropoietin may be used to reduce transfusion requirements. For those with moderate to severe hemolysis, we suggest
         <a class="drug drug_general" data-topicid="8475" href="/z/d/drug information/8475.html" rel="external">
          folic acid
         </a>
         supplementation (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ); a typical dose is 1 mg/day. Higher folic acid doses are required during pregnancy, as presented separately. (See
         <a class="local">
          'Overview of treatment'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/423.html" rel="external">
          "Preconception and prenatal folic acid supplementation"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Transfusions
         </strong>
         – Blood transfusion is often required in infancy, even in mild autosomal dominant HS. The transfusion requirement in the first months of life does not necessarily predict a severe phenotype. Transfusions may be needed in older children and adults in other settings (eg, aplastic or hemolytic crisis with infections, pregnancy). Typical hemoglobin thresholds for transfusion depend on the age of the patient, symptoms, and comorbidities. Transfusional iron overload may occur after transfusion of &gt;15 to 20 units of RBCs (&gt;10 units in smaller children), and appropriate monitoring is required, with chelation indicated in some cases. (See
         <a class="local">
          'Transfusions'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Splenectomy
         </strong>
         – For children with HS whose disease remains transfusion-dependent or who are severely symptomatic from anemia &gt;1 year of age because of
         <em>
          SPTA1
         </em>
         -associated autosomal recessive HS, we recommend a chronic transfusion program with chelation until they are at least three years of age. Partial splenectomy can be considered at that age (provided there is adequate surgical expertise) (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). We suggest postponing total splenectomy until &gt;5 years of age, after the appropriate pre-splenectomy immunizations are completed, to reduce the risk of sepsis. (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). Some families with children &gt;5 years old may elect to have a total splenectomy rather than partial splenectomy as the initial procedure. Observational data demonstrate a dramatic reduction in transfusion requirements after splenectomy. The use of splenectomy in individuals with moderate disease, typically autosomal dominant HS, is individualized based on symptoms (discomfort from splenomegaly, distress from jaundice). In those cases, partial splenectomy (provided there is adequate surgical expertise) may offer a better balance of benefits versus long-term risks. (See
         <a class="local">
          'Decision to pursue splenectomy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Pre-splenectomy considerations and splenectomy risks
         </strong>
         – For individuals considering splenectomy, all immunizations for encapsulated organisms should be administered with sufficient time to develop an antibody response. For individuals with gallstones, it may be possible to perform simultaneous cholecystectomy at the time of splenectomy. Patients should be aware of different operative techniques (partial versus total splenectomy; open versus laparoscopic procedures) and potential complications, which include potentially life-threatening sepsis, venous thromboembolism (VTE), and possibly arterial thromboembolic events or pulmonary hypertension. It is important to confirm that the patient does not have HSt, for which splenectomy is contraindicated since it is neither safe nor effective in limiting hemolysis. (See
         <a class="local">
          'Pre-splenectomy considerations'
         </a>
         above and
         <a class="local">
          'Operative techniques'
         </a>
         above and
         <a class="local">
          'Complications'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/117640.html" rel="external">
          "Elective (diagnostic or therapeutic) splenectomy", section on 'Postoperative risks'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Relatives
         </strong>
         – Testing relatives, reproductive testing, and/or genetic counseling may be useful. (See
         <a class="local">
          'Testing relatives; reproductive testing and counseling'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H865952729">
         <span class="h1">
          ACKNOWLEDGMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate gratefully acknowledges Stanley L Schrier, MD (deceased), who contributed as Section Editor on earlier versions of this topic and was a founding Editor-in-Chief for UpToDate in Hematology.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Lux SE 4th. Anatomy of the red cell membrane skeleton: unanswered questions. Blood 2016; 127:187.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Risinger M, Kalfa TA. Red cell membrane disorders: structure meets function. Blood 2020; 136:1250.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Narla J, Mohandas N. Red cell membrane disorders. Int J Lab Hematol 2017; 39 Suppl 1:47.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Eber S, Lux SE. Hereditary spherocytosis--defects in proteins that connect the membrane skeleton to the lipid bilayer. Semin Hematol 2004; 41:118.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jarolim P, Murray JL, Rubin HL, et al. Characterization of 13 novel band 3 gene defects in hereditary spherocytosis with band 3 deficiency. Blood 1996; 88:4366.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Eber SW, Gonzalez JM, Lux ML, et al. Ankyrin-1 mutations are a major cause of dominant and recessive hereditary spherocytosis. Nat Genet 1996; 13:214.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dhermy D, Galand C, Bournier O, et al. Heterogenous band 3 deficiency in hereditary spherocytosis related to different band 3 gene defects. Br J Haematol 1997; 98:32.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Falcón-Pérez JM, Dell'Angelica EC. The pallidin (Pldn) gene and the role of SNARE proteins in melanosome biogenesis. Pigment Cell Res 2002; 15:82.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moriyama K, Bonifacino JS. Pallidin is a component of a multi-protein complex involved in the biogenesis of lysosome-related organelles. Traffic 2002; 3:666.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Peters LL, Shivdasani RA, Liu SC, et al. Anion exchanger 1 (band 3) is required to prevent erythrocyte membrane surface loss but not to form the membrane skeleton. Cell 1996; 86:917.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Southgate CD, Chishti AH, Mitchell B, et al. Targeted disruption of the murine erythroid band 3 gene results in spherocytosis and severe haemolytic anaemia despite a normal membrane skeleton. Nat Genet 1996; 14:227.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Peters LL, Jindel HK, Gwynn B, et al. Mild spherocytosis and altered red cell ion transport in protein 4. 2-null mice. J Clin Invest 1999; 103:1527.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Peters LL, Lux SE. Ankyrins: structure and function in normal cells and hereditary spherocytes. Semin Hematol 1993; 30:85.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Inaba M, Yawata A, Koshino I, et al. Defective anion transport and marked spherocytosis with membrane instability caused by hereditary total deficiency of red cell band 3 in cattle due to a nonsense mutation. J Clin Invest 1996; 97:1804.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           White RA, Sokolovsky IV, Britt MI, et al. Hematologic characterization and chromosomal localization of the novel dominantly inherited mouse hemolytic anemia, neonatal anemia (Nan). Blood Cells Mol Dis 2009; 43:141.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Heruth DP, Hawkins T, Logsdon DP, et al. Mutation in erythroid specific transcription factor KLF1 causes Hereditary Spherocytosis in the Nan hemolytic anemia mouse model. Genomics 2010; 96:303.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nébor D, Graber JH, Ciciotte SL, et al. Mutant KLF1 in Adult Anemic Nan Mice Leads to Profound Transcriptome Changes and Disordered Erythropoiesis. Sci Rep 2018; 8:12793.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Arnaud L, Saison C, Helias V, et al. A dominant mutation in the gene encoding the erythroid transcription factor KLF1 causes a congenital dyserythropoietic anemia. Am J Hum Genet 2010; 87:721.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fournier CM, Nicolas G, Gallagher PG, et al. Spectrin St Claude, a splicing mutation of the human alpha-spectrin gene associated with severe poikilocytic anemia. Blood 1997; 89:4584.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jarolim P, Wichterle H, Hanspal M, et al. Beta spectrin PRAGUE: a truncated beta spectrin producing spectrin deficiency, defective spectrin heterodimer self-association and a phenotype of spherocytic elliptocytosis. Br J Haematol 1995; 91:502.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gibson SJ, Kalfa TA, DeStefano CB. Insane in the membrane: A case of hereditary spherocytic pyropoikilocytosis. Am J Hematol 2022; 97:1384.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mohandas N, Gallagher PG. Red cell membrane: past, present, and future. Blood 2008; 112:3939.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Andolfo I, Russo R, Gambale A, Iolascon A. New insights on hereditary erythrocyte membrane defects. Haematologica 2016; 101:1284.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mohandas N. Inherited hemolytic anemia: a possessive beginner's guide. Hematology Am Soc Hematol Educ Program 2018; 2018:377.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gallagher PG. Red cell membrane disorders. Hematology Am Soc Hematol Educ Program 2005; :13.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Randon J, Miraglia del Giudice E, Bozon M, et al. Frequent de novo mutations of the ANK1 gene mimic a recessive mode of transmission in hereditary spherocytosis: three new ANK1 variants: ankyrins Bari, Napoli II and Anzio. Br J Haematol 1997; 96:500.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           del Giudice EM, Hayette S, Bozon M, et al. Ankyrin Napoli: a de novo deletional frameshift mutation in exon 16 of ankyrin gene (ANK1) associated with spherocytosis. Br J Haematol 1996; 93:828.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Morlé L, Bozon M, Alloisio N, et al. Ankyrin Bugey: a de novo deletional frameshift variant in exon 6 of the ankyrin gene associated with spherocytosis. Am J Hematol 1997; 54:242.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Miraglia del Giudice E, Francese M, Nobili B, et al. High frequency of de novo mutations in ankyrin gene (ANK1) in children with hereditary spherocytosis. J Pediatr 1998; 132:117.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Miraglia del Giudice E, Lombardi C, Francese M, et al. Frequent de novo monoallelic expression of beta-spectrin gene (SPTB) in children with hereditary spherocytosis and isolated spectrin deficiency. Br J Haematol 1998; 101:251.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Miraglia del Giudice E, Nobili B, Francese M, et al. Clinical and molecular evaluation of non-dominant hereditary spherocytosis. Br J Haematol 2001; 112:42.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Iolascon A, Miraglia del Giudice E, Perrotta S, et al. Hereditary spherocytosis: from clinical to molecular defects. Haematologica 1998; 83:240.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ribeiro ML, Alloisio N, Almeida H, et al. Severe hereditary spherocytosis and distal renal tubular acidosis associated with the total absence of band 3. Blood 2000; 96:1602.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kager L, Bruce LJ, Zeitlhofer P, et al. Band 3 nullVIENNA , a novel homozygous SLC4A1 p.Ser477X variant causing severe hemolytic anemia, dyserythropoiesis and complete distal renal tubular acidosis. Pediatr Blood Cancer 2017; 64.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chonat S, Risinger M, Sakthivel H, et al. The Spectrum of SPTA1-Associated Hereditary Spherocytosis. Front Physiol 2019; 10:815.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stenson PD, Mort M, Ball EV, et al. The Human Gene Mutation Database (HGMD®): optimizing its use in a clinical diagnostic or research setting. Hum Genet 2020; 139:1197.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stenson PD, Ball EV, Mort M, et al. Human Gene Mutation Database (HGMD): 2003 update. Hum Mutat 2003; 21:577.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gallagher PG. Hematologically important mutations: ankyrin variants in hereditary spherocytosis. Blood Cells Mol Dis 2005; 35:345.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Luo Y, Li Z, Huang L, et al. Spectrum of Ankyrin Mutations in Hereditary Spherocytosis: A Case Report and Review of the Literature. Acta Haematol 2018; 140:77.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Begtrup AH, Dagaonkar N, Pushkaran S, et al. Development of a comprehensive rapid next-generation sequencing assay for the diagnosis of inherited hemolytic anemia. Blood 2013; 122:949.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Okamoto N, Wada Y, Nakamura Y, et al. Hereditary spherocytic anemia with deletion of the short arm of chromosome 8. Am J Med Genet 1995; 58:225.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jarolim P, Rubin HL, Brabec V, et al. Mutations of conserved arginines in the membrane domain of erythroid band 3 lead to a decrease in membrane-associated band 3 and to the phenotype of hereditary spherocytosis. Blood 1995; 85:634.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lima PR, Gontijo JA, Lopes de Faria JB, et al. Band 3 Campinas: a novel splicing mutation in the band 3 gene (AE1) associated with hereditary spherocytosis, hyperactivity of Na+/Li+ countertransport and an abnormal renal bicarbonate handling. Blood 1997; 90:2810.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jenkins PB, Abou-Alfa GK, Dhermy D, et al. A nonsense mutation in the erythrocyte band 3 gene associated with decreased mRNA accumulation in a kindred with dominant hereditary spherocytosis. J Clin Invest 1996; 97:373.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Miraglia del Giudice E, Vallier A, Maillet P, et al. Novel band 3 variants (bands 3 Foggia, Napoli I and Napoli II) associated with hereditary spherocytosis and band 3 deficiency: status of the D38A polymorphism within the EPB3 locus. Br J Haematol 1997; 96:70.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Maillet P, Vallier A, Reinhart WH, et al. Band 3 Chur: a variant associated with band 3-deficient hereditary spherocytosis and substitution in a highly conserved position of transmembrane segment 11. Br J Haematol 1995; 91:804.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bianchi P, Zanella A, Alloisio N, et al. A variant of the EPB3 gene of the anti-Lepore type in hereditary spherocytosis. Br J Haematol 1997; 98:283.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tole S, Dhir P, Pugi J, et al. Genotype-phenotype correlation in children with hereditary spherocytosis. Br J Haematol 2020; 191:486.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Alloisio N, Texier P, Vallier A, et al. Modulation of clinical expression and band 3 deficiency in hereditary spherocytosis. Blood 1997; 90:414.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Alloisio N, Maillet P, Carré G, et al. Hereditary spherocytosis with band 3 deficiency. Association with a nonsense mutation of the band 3 gene (allele Lyon), and aggravation by a low-expression allele occurring in trans (allele Genas). Blood 1996; 88:1062.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Liu SC, Zhai S, Palek J, et al. Molecular defect of the band 3 protein in southeast Asian ovalocytosis. N Engl J Med 1990; 323:1530.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jarolim P, Palek J, Amato D, et al. Deletion in erythrocyte band 3 gene in malaria-resistant Southeast Asian ovalocytosis. Proc Natl Acad Sci U S A 1991; 88:11022.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bruce LJ, Cope DL, Jones GK, et al. Familial distal renal tubular acidosis is associated with mutations in the red cell anion exchanger (Band 3, AE1) gene. J Clin Invest 1997; 100:1693.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Karet FE, Gainza FJ, Györy AZ, et al. Mutations in the chloride-bicarbonate exchanger gene AE1 cause autosomal dominant but not autosomal recessive distal renal tubular acidosis. Proc Natl Acad Sci U S A 1998; 95:6337.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jarolim P, Shayakul C, Prabakaran D, et al. Autosomal dominant distal renal tubular acidosis is associated in three families with heterozygosity for the R589H mutation in the AE1 (band 3) Cl-/HCO3- exchanger. J Biol Chem 1998; 273:6380.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Toye AM, Williamson RC, Khanfar M, et al. Band 3 Courcouronnes (Ser667Phe): a trafficking mutant differentially rescued by wild-type band 3 and glycophorin A. Blood 2008; 111:5380.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chu C, Woods N, Sawasdee N, et al. Band 3 Edmonton I, a novel mutant of the anion exchanger 1 causing spherocytosis and distal renal tubular acidosis. Biochem J 2010; 426:379.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chang YH, Shaw CF, Jian SH, et al. Compound mutations in human anion exchanger 1 are associated with complete distal renal tubular acidosis and hereditary spherocytosis. Kidney Int 2009; 76:774.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kittanakom S, Cordat E, Reithmeier RA. Dominant-negative effect of Southeast Asian ovalocytosis anion exchanger 1 in compound heterozygous distal renal tubular acidosis. Biochem J 2008; 410:271.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Figueroa D. The Diego blood group system: a review. Immunohematology 2013; 29:73.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rybicki AC, Qiu JJ, Musto S, et al. Human erythrocyte protein 4.2 deficiency associated with hemolytic anemia and a homozygous 40glutamic acid--&gt;lysine substitution in the cytoplasmic domain of band 3 (band 3Montefiore). Blood 1993; 81:2155.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Barneaud-Rocca D, Borgese F, Guizouarn H. Dual transport properties of anion exchanger 1: the same transmembrane segment is involved in anion exchange and in a cation leak. J Biol Chem 2011; 286:8909.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bruce LJ, Robinson HC, Guizouarn H, et al. Monovalent cation leaks in human red cells caused by single amino-acid substitutions in the transport domain of the band 3 chloride-bicarbonate exchanger, AE1. Nat Genet 2005; 37:1258.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bruce LJ. Hereditary stomatocytosis and cation-leaky red cells--recent developments. Blood Cells Mol Dis 2009; 42:216.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gallagher PG. Disorders of erythrocyte hydration. Blood 2017; 130:2699.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Iolascon A, De Falco L, Borgese F, et al. A novel erythroid anion exchange variant (Gly796Arg) of hereditary stomatocytosis associated with dyserythropoiesis. Haematologica 2009; 94:1049.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Becker PS, Lux SE. Hereditary spherocytosis and related disorders. Clin Haematol 1985; 14:15.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aggarwal A, Jamwal M, Sharma P, et al. Deciphering molecular heterogeneity of Indian families with hereditary spherocytosis using targeted next-generation sequencing: First South Asian study. Br J Haematol 2020; 188:784.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hassoun H, Vassiliadis JN, Murray J, et al. Characterization of the underlying molecular defect in hereditary spherocytosis associated with spectrin deficiency. Blood 1997; 90:398.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Becker PS, Tse WT, Lux SE, Forget BG. Beta spectrin kissimmee: a spectrin variant associated with autosomal dominant hereditary spherocytosis and defective binding to protein 4.1. J Clin Invest 1993; 92:612.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dhermy D, Galand C, Bournier O, et al. Hereditary spherocytosis with spectrin deficiency related to null mutations of the beta-spectrin gene. Blood Cells Mol Dis 1998; 24:251.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Garbarz M, Galand C, Bibas D, et al. A 5' splice region G--&gt;C mutation in exon 3 of the human beta-spectrin gene leads to decreased levels of beta-spectrin mRNA and is responsible for dominant hereditary spherocytosis (spectrin Guemene-Penfao). Br J Haematol 1998; 100:90.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hassoun H, Vassiliadis JN, Murray J, et al. Molecular basis of spectrin deficiency in beta spectrin Durham. A deletion within beta spectrin adjacent to the ankyrin-binding site precludes spectrin attachment to the membrane in hereditary spherocytosis. J Clin Invest 1995; 96:2623.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hassoun H, Vassiliadis JN, Murray J, et al. Hereditary spherocytosis with spectrin deficiency due to an unstable truncated beta spectrin. Blood 1996; 87:2538.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Maciag M, Płochocka D, Adamowicz-Salach A, Burzyńska B. Novel beta-spectrin mutations in hereditary spherocytosis associated with decreased levels of mRNA. Br J Haematol 2009; 146:326.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fermo E, Vercellati C, Marcello AP, et al. Targeted Next Generation Sequencing and Diagnosis of Congenital Hemolytic Anemias: A Three Years Experience Monocentric Study. Front Physiol 2021; 12:684569.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tse WT, Gallagher PG, Jenkins PB, et al. Amino-acid substitution in alpha-spectrin commonly coinherited with nondominant hereditary spherocytosis. Am J Hematol 1997; 54:233.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bogardus H, Schulz VP, Maksimova Y, et al. Severe nondominant hereditary spherocytosis due to uniparental isodisomy at the SPTA1 locus. Haematologica 2014; 99:e168.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wichterle H, Hanspal M, Palek J, Jarolim P. Combination of two mutant alpha spectrin alleles underlies a severe spherocytic hemolytic anemia. J Clin Invest 1996; 98:2300.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gallagher PG, Maksimova Y, Lezon-Geyda K, et al. Aberrant splicing contributes to severe α-spectrin-linked congenital hemolytic anemia. J Clin Invest 2019; 129:2878.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kalfa TA. Diagnosis and clinical management of red cell membrane disorders. Hematology Am Soc Hematol Educ Program 2021; 2021:331.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yawata Y, Yawata A, Kanzaki A, et al. Electron microscopic evidence of impaired intramembrane particles and instability of the cytoskeletal network in band 4.2 deficiency in human red cells. Cell Motil Cytoskeleton 1996; 33:95.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Perrotta S, Iolascon A, Polito R, et al. 4.2 Nippon mutation in a non-Japanese patient with hereditary spherocytosis. Haematologica 1999; 84:660.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hammill AM, Risinger MA, Joiner CH, et al. Compound heterozygosity for two novel mutations in the erythrocyte protein 4.2 gene causing spherocytosis in a Caucasian patient. Br J Haematol 2011; 152:780.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bouhassira EE, Schwartz RS, Yawata Y, et al. An alanine-to-threonine substitution in protein 4.2 cDNA is associated with a Japanese form of hereditary hemolytic anemia (protein 4.2NIPPON). Blood 1992; 79:1846.
          </a>
         </li>
         <li class="breakAll">
          Kalfa TA, Begtrup AH. EPB42-Related Hereditary Spherocytosis. In: GeneReviews, Adam MP, Mirzaa GM, Pagon RA, Wallace SE, Bean LJH (Eds), University of Washington, Seattle, Seattle (WA) 1993.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Takaoka Y, Ideguchi H, Matsuda M, et al. A novel mutation in the erythrocyte protein 4.2 gene of Japanese patients with hereditary spherocytosis (protein 4.2 Fukuoka). Br J Haematol 1994; 88:527.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kanzaki A, Yasunaga M, Okamoto N, et al. Band 4.2 Shiga: 317 CGC--&gt;TGC in compound heterozygotes with 142 GCT--&gt;ACT results in band 4.2 deficiency and microspherocytosis. Br J Haematol 1995; 91:333.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Matsuda M, Hatano N, Ideguchi H, et al. A novel mutation causing an aberrant splicing in the protein 4.2 gene associated with hereditary spherocytosis (protein 4.2Notame). Hum Mol Genet 1995; 4:1187.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van den Akker E, Satchwell TJ, Pellegrin S, et al. Investigating the key membrane protein changes during in vitro erythropoiesis of protein 4.2 (-) cells (mutations Chartres 1 and 2). Haematologica 2010; 95:1278.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jarolim P, Palek J, Rubin HL, et al. Band 3 Tuscaloosa: Pro327----Arg327 substitution in the cytoplasmic domain of erythrocyte band 3 protein associated with spherocytic hemolytic anemia and partial deficiency of protein 4.2. Blood 1992; 80:523.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Inoue T, Kanzaki A, Kaku M, et al. Homozygous missense mutation (band 3 Fukuoka: G130R): a mild form of hereditary spherocytosis with near-normal band 3 content and minimal changes of membrane ultrastructure despite moderate protein 4.2 deficiency. Br J Haematol 1998; 102:932.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kanzaki A, Hayette S, Morlé L, et al. Total absence of protein 4.2 and partial deficiency of band 3 in hereditary spherocytosis. Br J Haematol 1997; 99:522.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bustos SP, Reithmeier RA. Structure and stability of hereditary spherocytosis mutants of the cytosolic domain of the erythrocyte anion exchanger 1 protein. Biochemistry 2006; 45:1026.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Salomao M, Chen K, Villalobos J, et al. Hereditary spherocytosis and hereditary elliptocytosis: aberrant protein sorting during erythroblast enucleation. Blood 2010; 116:267.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           An X, Mohandas N. Disorders of red cell membrane. Br J Haematol 2008; 141:367.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Perrotta S, Gallagher PG, Mohandas N. Hereditary spherocytosis. Lancet 2008; 372:1411.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bolton-Maggs PH, Stevens RF, Dodd NJ, et al. Guidelines for the diagnosis and management of hereditary spherocytosis. Br J Haematol 2004; 126:455.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Da Costa L, Mohandas N, Sorette M, et al. Temporal differences in membrane loss lead to distinct reticulocyte features in hereditary spherocytosis and in immune hemolytic anemia. Blood 2001; 98:2894.
          </a>
         </li>
         <li class="breakAll">
          Lux SE, Palek J. Disorders of the red cell membrane. In: Blood. Principles and Practice of Hematology, Handin RI, Lux SE, Stossel TP (Eds), Lippincott, Philadelphia 1995. p.1701.
         </li>
         <li>
          <a class="nounderline abstract_t">
           De Franceschi L, Olivieri O, Miraglia del Giudice E, et al. Membrane cation and anion transport activities in erythrocytes of hereditary spherocytosis: effects of different membrane protein defects. Am J Hematol 1997; 55:121.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Joiner CH, Franco RS, Jiang M, et al. Increased cation permeability in mutant mouse red blood cells with defective membrane skeletons. Blood 1995; 86:4307.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Safeukui I, Buffet PA, Deplaine G, et al. Quantitative assessment of sensing and sequestration of spherocytic erythrocytes by the human spleen. Blood 2012; 120:424.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Klei TRL, Dalimot J, Nota B, et al. Hemolysis in the spleen drives erythrocyte turnover. Blood 2020; 136:1579.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Agre P, Orringer EP, Bennett V. Deficient red-cell spectrin in severe, recessively inherited spherocytosis. N Engl J Med 1982; 306:1155.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schrier SL. What does the spleen see? Blood 2012; 120:242.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Li H, Lu L, Li X, et al. Mechanics of diseased red blood cells in human spleen and consequences for hereditary blood disorders. Proc Natl Acad Sci U S A 2018; 115:9574.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ingrosso D, D'Angelo S, Perrotta S, et al. Cytoskeletal behaviour in spectrin and in band 3 deficient spherocytic red cells: evidence for differentiated splenic conditioning role. Br J Haematol 1996; 93:38.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van Zwieten R, van Oirschot BA, Veldthuis M, et al. Partial pyruvate kinase deficiency aggravates the phenotypic expression of band 3 deficiency in a family with hereditary spherocytosis. Am J Hematol 2015; 90:E35.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Andres O, Loewecke F, Morbach H, et al. Hereditary spherocytosis is associated with decreased pyruvate kinase activity due to impaired structural integrity of the red blood cell membrane. Br J Haematol 2019; 187:386.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Eber SW, Pekrun A, Neufeldt A, Schröter W. Prevalence of increased osmotic fragility of erythrocytes in German blood donors: screening using a modified glycerol lysis test. Ann Hematol 1992; 64:88.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Saada V, Cynober T, Brossard Y, et al. Incidence of hereditary spherocytosis in a population of jaundiced neonates. Pediatr Hematol Oncol 2006; 23:387.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van Vuren A, van der Zwaag B, Huisjes R, et al. The Complexity of Genotype-Phenotype Correlations in Hereditary Spherocytosis: A Cohort of 95 Patients: Genotype-Phenotype Correlation in Hereditary Spherocytosis. Hemasphere 2019; 3:e276.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Whitfield CF, Follweiler JB, Lopresti-Morrow L, Miller BA. Deficiency of alpha-spectrin synthesis in burst-forming units-erythroid in lethal hereditary spherocytosis. Blood 1991; 78:3043.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Friedman EW, Williams JC, Van Hook L. Hereditary spherocytosis in the elderly. Am J Med 1988; 84:513.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Eber SW, Armbrust R, Schröter W. Variable clinical severity of hereditary spherocytosis: relation to erythrocytic spectrin concentration, osmotic fragility, and autohemolysis. J Pediatr 1990; 117:409.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           del Giudice EM, Perrotta S, Nobili B, et al. Coinheritance of Gilbert syndrome increases the risk for developing gallstones in patients with hereditary spherocytosis. Blood 1999; 94:2259.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bolton-Maggs PH, Langer JC, Iolascon A, et al. Guidelines for the diagnosis and management of hereditary spherocytosis--2011 update. Br J Haematol 2012; 156:37.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Christensen RD, Yaish HM, Gallagher PG. A pediatrician's practical guide to diagnosing and treating hereditary spherocytosis in neonates. Pediatrics 2015; 135:1107.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Delhommeau F, Cynober T, Schischmanoff PO, et al. Natural history of hereditary spherocytosis during the first year of life. Blood 2000; 95:393.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schröter W, Kahsnitz E. Diagnosis of hereditary spherocytosis in newborn infants. J Pediatr 1983; 103:460.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tchernia G, Delhommeau F, Perrotta S, et al. Recombinant erythropoietin therapy as an alternative to blood transfusions in infants with hereditary spherocytosis. Hematol J 2000; 1:146.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Elbadry MI, Khaled SAA, Ahmed NM, et al. Acute human parvovirus B19 infection triggers immune-mediated transient bone marrow failure syndrome, extreme direct hyperbilirubinaemia and acute hepatitis in patients with hereditary haemolytic anaemias: multicentre prospective pathophysiological study. Br J Haematol 2021; 193:827.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Taher AT, Iolascon A, Matar CF, et al. Recommendations for Pregnancy in Rare Inherited Anemias. Hemasphere 2020; 4:e446.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pitkin RM. Folate and neural tube defects. Am J Clin Nutr 2007; 85:285S.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fisher AL, Sangkhae V, Balušíková K, et al. Iron-dependent apoptosis causes embryotoxicity in inflamed and obese pregnancy. Nat Commun 2021; 12:4026.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bastion Y, Coiffier B, Felman P, et al. Massive mediastinal extramedullary hematopoiesis in hereditary spherocytosis: a case report. Am J Hematol 1990; 35:263.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Smith J, Rahilly M, Davidson K. Extramedullary haematopoiesis secondary to hereditary spherocytosis. Br J Haematol 2011; 154:543.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tole S, Amid A, Baker J, et al. Mild Hereditary Spherocytosis without Accompanying Hereditary Haemochromatosis: An Unrecognised Cause of Iron Overload. Acta Haematol 2019; 141:256.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rabhi S, Benjelloune H, Meziane M, et al. Hereditary spherocytosis with leg ulcers healing after splenectomy. South Med J 2011; 104:150.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Prabhakaran K, Jacobs BL, Smaldone MC, Franks ME. Stuttering priapism associated with hereditary spherocytosis. Can J Urol 2007; 14:3702.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Christensen RD, Henry E. Hereditary spherocytosis in neonates with hyperbilirubinemia. Pediatrics 2010; 125:120.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           MACKINNEY AA Jr. HEREDITARY SPHEROCYTOSIS; CLINICAL FAMILY STUDIES. Arch Intern Med 1965; 116:257.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           BATES GC, BROWN CH. Incidence of gallbladder disease in chronic hemolytic anemia (spherocytosis). Gastroenterology 1952; 21:104.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ruparel RK, Bogert JN, Moir CR, et al. Synchronous splenectomy during cholecystectomy for hereditary spherocytosis: is it really necessary? J Pediatr Surg 2014; 49:433.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schilling RF. Risks and benefits of splenectomy versus no splenectomy for hereditary spherocytosis--a personal view. Br J Haematol 2009; 145:728.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schilling RF, Gangnon RE, Traver MI. Delayed adverse vascular events after splenectomy in hereditary spherocytosis. J Thromb Haemost 2008; 6:1289.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Segel GB, Lichtman MA. Direct antiglobulin ("Coombs") test-negative autoimmune hemolytic anemia: a review. Blood Cells Mol Dis 2014; 52:152.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kalfa TA. Warm antibody autoimmune hemolytic anemia. Hematology Am Soc Hematol Educ Program 2016; 2016:690.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Voulgaridou A, Kalfa TA. Autoimmune Hemolytic Anemia in the Pediatric Setting. J Clin Med 2021; 10.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           King MJ, Garçon L, Hoyer JD, et al. ICSH guidelines for the laboratory diagnosis of nonimmune hereditary red cell membrane disorders. Int J Lab Hematol 2015; 37:304.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Coetzer TL, Lawler J, Liu SC, et al. Partial ankyrin and spectrin deficiency in severe, atypical hereditary spherocytosis. N Engl J Med 1988; 318:230.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Palek J, Jarolim P. Clinical expression and laboratory detection of red blood cell membrane protein mutations. Semin Hematol 1993; 30:249.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Michaels LA, Cohen AR, Zhao H, et al. Screening for hereditary spherocytosis by use of automated erythrocyte indexes. J Pediatr 1997; 130:957.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ciepiela O, Kotuła I, Górska E, et al. Delay in the measurement of eosin-5′-maleimide (EMA) binding does not affect the test result for the diagnosis of hereditary spherocytosis. Clin Chem Lab Med 2013; 51:817.
          </a>
         </li>
         <li class="breakAll">
          Hoffman R, Benz EJ Jr, Silberstein LE, et al. Red blood cell membrane disorders. In: Hematology: Basic Principles and Practice, 7th ed, Hoffman R, Benz EJ Jr, Silberstein LE, et al (Eds), Elsevier, Philadelphia 2018. p.632.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bianchi P, Fermo E, Vercellati C, et al. Diagnostic power of laboratory tests for hereditary spherocytosis: a comparison study in 150 patients grouped according to molecular and clinical characteristics. Haematologica 2012; 97:516.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           King MJ, Behrens J, Rogers C, et al. Rapid flow cytometric test for the diagnosis of membrane cytoskeleton-associated haemolytic anaemia. Br J Haematol 2000; 111:924.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Crisp RL, Solari L, Gammella D, et al. Use of capillary blood to diagnose hereditary spherocytosis. Pediatr Blood Cancer 2012; 59:1299.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Christensen RD, Agarwal AM, Nussenzveig RH, et al. Evaluating eosin-5-maleimide binding as a diagnostic test for hereditary spherocytosis in newborn infants. J Perinatol 2015; 35:357.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cheli E, Roze J, Garrot T, et al. Usefulness of the EMA flow cytometric test in the diagnosis of hereditary spherocytosis post-transfusion. Br J Haematol 2017; 178:180.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kar R, Mishra P, Pati HP. Evaluation of eosin-5-maleimide flow cytometric test in diagnosis of hereditary spherocytosis. Int J Lab Hematol 2010; 32:8.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stoya G, Gruhn B, Vogelsang H, et al. Flow cytometry as a diagnostic tool for hereditary spherocytosis. Acta Haematol 2006; 116:186.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Crisp RL, Solari L, Vota D, et al. A prospective study to assess the predictive value for hereditary spherocytosis using five laboratory tests (cryohemolysis test, eosin-5'-maleimide flow cytometry, osmotic fragility test, autohemolysis test, and SDS-PAGE) on 50 hereditary spherocytosis families in Argentina. Ann Hematol 2011; 90:625.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ciepiela O, Nowak M, Wrońska M, et al. Eosin-5'-maleimide binding test-Do we use appropriate reference values to detect hereditary spherocytosis in neonates? Int J Lab Hematol 2019; 41:e57.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Da Costa L, Suner L, Galimand J, et al. Diagnostic tool for red blood cell membrane disorders: Assessment of a new generation ektacytometer. Blood Cells Mol Dis 2016; 56:9.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cynober T, Mohandas N, Tchernia G. Red cell abnormalities in hereditary spherocytosis: relevance to diagnosis and understanding of the variable expression of clinical severity. J Lab Clin Med 1996; 128:259.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bessis M, Mohandas N, Feo C. Automated ektacytometry: a new method of measuring red cell deformability and red cell indices. Blood Cells 1980; 6:315.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mohandas N, Clark MR, Jacobs MS, Shohet SB. Analysis of factors regulating erythrocyte deformability. J Clin Invest 1980; 66:563.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zaninoni A, Fermo E, Vercellati C, et al. Use of Laser Assisted Optical Rotational Cell Analyzer (LoRRca MaxSis) in the Diagnosis of RBC Membrane Disorders, Enzyme Defects, and Congenital Dyserythropoietic Anemias: A Monocentric Study on 202 Patients. Front Physiol 2018; 9:451.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bucx MJ, Breed WP, Hoffmann JJ. Comparison of acidified glycerol lysis test, Pink test and osmotic fragility test in hereditary spherocytosis: effect of incubation. Eur J Haematol 1988; 40:227.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Judkiewicz L, Szczepanek A, Bugała I, Bartosz G. Modified end-point glycerol hemolysis assay as a screening test for hereditary spherocytosis that requires no venipuncture. Am J Hematol 1987; 26:89.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Streichman S, Gescheidt Y. Cryohemolysis for the detection of hereditary spherocytosis: correlation studies with osmotic fragility and autohemolysis. Am J Hematol 1998; 58:206.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Romero RR, Poo JL, Robles JA, et al. Usefulness of cryohemolysis test in the diagnosis of hereditary spherocytosis. Arch Med Res 1997; 28:247.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Iolascon A, Andolfo I, Barcellini W, et al. Recommendations regarding splenectomy in hereditary hemolytic anemias. Haematologica 2017; 102:1304.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stewart GW, Amess JA, Eber SW, et al. Thrombo-embolic disease after splenectomy for hereditary stomatocytosis. Br J Haematol 1996; 93:303.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Picard V, Guitton C, Thuret I, et al. Clinical and biological features in PIEZO1-hereditary xerocytosis and Gardos channelopathy: a retrospective series of 126 patients. Haematologica 2019; 104:1554.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           El Nabouch M, Rakotoharinandrasana I, Ndayikeza A, et al. Infantile pyknocytosis, a rare cause of hemolytic anemia in newborns: report of two cases in twin girls and literature overview. Clin Case Rep 2015; 3:535.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Anselstetter V, Horstmann HJ, Heimpel H. Congenital dyserythropoietic anaemia, types I and II: aberrant pattern of erythrocyte membrane proteins in CDA II, as revealed by two-dimensional polyacrylamide gel electrophoresis. Br J Haematol 1977; 35:209.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rothman JA, Stevens JL, Gray FL, Kalfa TA. How I approach hereditary hemolytic anemia and splenectomy. Pediatr Blood Cancer 2020; 67:e28337.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Manno CS, Cohen AR. Splenectomy in mild hereditary spherocytosis: is it worth the risk? Am J Pediatr Hematol Oncol 1989; 11:300.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kimura F, Ito H, Shimizu H, et al. Partial splenic embolization for the treatment of hereditary spherocytosis. AJR Am J Roentgenol 2003; 181:1021.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pincez T, Guitton C, Gauthier F, et al. Long-term follow-up of subtotal splenectomy for hereditary spherocytosis: a single-center study. Blood 2016; 127:1616.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rice HE, Englum BR, Rothman J, et al. Clinical outcomes of splenectomy in children: report of the splenectomy in congenital hemolytic anemia registry. Am J Hematol 2015; 90:187.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Englum BR, Rothman J, Leonard S, et al. Hematologic outcomes after total splenectomy and partial splenectomy for congenital hemolytic anemia. J Pediatr Surg 2016; 51:122.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Buesing KL, Tracy ET, Kiernan C, et al. Partial splenectomy for hereditary spherocytosis: a multi-institutional review. J Pediatr Surg 2011; 46:178.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Slater BJ, Chan FP, Davis K, Dutta S. Institutional experience with laparoscopic partial splenectomy for hereditary spherocytosis. J Pediatr Surg 2010; 45:1682.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rosman CWK, Broens PMA, Trzpis M, Tamminga RYJ. A long-term follow-up study of subtotal splenectomy in children with hereditary spherocytosis. Pediatr Blood Cancer 2017; 64.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pugi J, Carcao M, Drury LJ, Langer JC. Results after laparoscopic partial splenectomy for children with hereditary spherocytosis: Are outcomes influenced by genetic mutation? J Pediatr Surg 2018; 53:973.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Das A, Bansal D, Das R, et al. Hereditary spherocytosis in children: profile and post-splenectomy outcome. Indian Pediatr 2014; 51:139.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Oliveira MC, Fernandes RA, Rodrigues CL, et al. Clinical course of 63 children with hereditary spherocytosis: a retrospective study. Rev Bras Hematol Hemoter 2012; 34:9.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lee BJH, Yap QV, Low JK, et al. Cholecystectomy for asymptomatic gallstones: Markov decision tree analysis. World J Clin Cases 2022; 10:10399.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mackenzie AE, Elliot DH, Eastcott HH, et al. Relapse in hereditary spherocytosis with proven splenunculus. Lancet 1962; 1:1102.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Curran TJ, Foley MI, Swanstrom LL, Campbell TJ. Laparoscopy improves outcomes for pediatric splenectomy. J Pediatr Surg 1998; 33:1498.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rescorla FJ, Breitfeld PP, West KW, et al. A case controlled comparison of open and laparoscopic splenectomy in children. Surgery 1998; 124:670.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tanoue K, Okita K, Akahoshi T, et al. Laparoscopic splenectomy for hematologic diseases. Surgery 2002; 131:S318.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wood JH, Partrick DA, Hays T, et al. Contemporary pediatric splenectomy: continuing controversies. Pediatr Surg Int 2011; 27:1165.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rescorla FJ, West KW, Engum SA, Grosfeld JL. Laparoscopic splenic procedures in children: experience in 231 children. Ann Surg 2007; 246:683.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Delaitre B, Champault G, Barrat C, et al. [Laparoscopic splenectomy for hematologic diseases. Study of 275 cases. French Society of Laparoscopic Surgery]. Ann Chir 2000; 125:522.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shakya VC, Byanjankar B, Pandit R, et al. Challenges and Results of Laparoscopic Splenectomy for Hematological Diseases in a Developing Country. Minim Invasive Surg 2018; 2018:4256570.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bader-Meunier B, Gauthier F, Archambaud F, et al. Long-term evaluation of the beneficial effect of subtotal splenectomy for management of hereditary spherocytosis. Blood 2001; 97:399.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tchernia G, Bader-Meunier B, Berterottiere P, et al. Effectiveness of partial splenectomy in hereditary spherocytosis. Curr Opin Hematol 1997; 4:136.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stoehr GA, Stauffer UG, Eber SW. Near-total splenectomy: a new technique for the management of hereditary spherocytosis. Ann Surg 2005; 241:40.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stoehr GA, Sobh JN, Luecken J, et al. Near-total splenectomy for hereditary spherocytosis: clinical prospects in relation to disease severity. Br J Haematol 2006; 132:791.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dutta S, Price VE, Blanchette V, Langer JC. A laparoscopic approach to partial splenectomy for children with hereditary spherocytosis. Surg Endosc 2006; 20:1719.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tracy ET, Rice HE. Partial splenectomy for hereditary spherocytosis. Pediatr Clin North Am 2008; 55:503.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Morinis J, Dutta S, Blanchette V, et al. Laparoscopic partial vs total splenectomy in children with hereditary spherocytosis. J Pediatr Surg 2008; 43:1649.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vasilescu C, Stanciulea O, Tudor S. Laparoscopic versus robotic subtotal splenectomy in hereditary spherocytosis. Potential advantages and limits of an expensive approach. Surg Endosc 2012; 26:2802.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vasilescu C, Stanciulea O, Tudor S, et al. Laparoscopic subtotal splenectomy in hereditary spherocytosis : to preserve the upper or the lower pole of the spleen? Surg Endosc 2006; 20:748.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Liu G, Fan Y. Feasibility and Safety of Laparoscopic Partial Splenectomy: A Systematic Review. World J Surg 2019; 43:1505.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Agre P, Asimos A, Casella JF, McMillan C. Inheritance pattern and clinical response to splenectomy as a reflection of erythrocyte spectrin deficiency in hereditary spherocytosis. N Engl J Med 1986; 315:1579.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Luu S, Spelman D, Woolley IJ. Post-splenectomy sepsis: preventative strategies, challenges, and solutions. Infect Drug Resist 2019; 12:2839.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Singer DB. Postsplenectomy sepsis. Perspect Pediatr Pathol 1973; 1:285.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schilling RF. Estimating the risk for sepsis after splenectomy in hereditary spherocytosis. Ann Intern Med 1995; 122:187.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jugenburg M, Haddock G, Freedman MH, et al. The morbidity and mortality of pediatric splenectomy: does prophylaxis make a difference? J Pediatr Surg 1999; 34:1064.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Konradsen HB, Henrichsen J. Pneumococcal infections in splenectomized children are preventable. Acta Paediatr Scand 1991; 80:423.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Davidsen C, Larsen TH, Gerdts E, Lønnebakken MT. Giant right ventricular outflow tract thrombus in hereditary spherocytosis: a case report. Thromb J 2016; 14:9.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Perkins LA, Jones SF, Bhargava RS. Dural venous thrombosis following splenectomy in a patient with hereditary spherocytosis. South Med J 2009; 102:542.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schilling RF. Spherocytosis, splenectomy, strokes, and heat attacks. Lancet 1997; 350:1677.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Smedema JP, Louw VJ. Pulmonary arterial hypertension after splenectomy for hereditary spherocytosis. Cardiovasc J Afr 2007; 18:84.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Verresen D, De Backer W, Van Meerbeeck J, et al. Spherocytosis and pulmonary hypertension coincidental occurrence or causal relationship? Eur Respir J 1991; 4:629.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hayag-Barin JE, Smith RE, Tucker FC Jr. Hereditary spherocytosis, thrombocytosis, and chronic pulmonary emboli: a case report and review of the literature. Am J Hematol 1998; 57:82.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tso SC, Chan TK, Todd D. Venous thrombosis in haemoglobin H disease after splenectomy. Aust N Z J Med 1982; 12:635.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Robinette CD, Fraumeni JF Jr. Splenectomy and subsequent mortality in veterans of the 1939-45 war. Lancet 1977; 2:127.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bhargava K, Chandra N, Omar AK, Mathur A. Protein C deficiency leading to pulmonary thromboembolism in a patient with hereditary spherocytosis. Indian Heart J 2006; 58:444.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Das A, Bansal D, Ahluwalia J, et al. Risk factors for thromboembolism and pulmonary artery hypertension following splenectomy in children with hereditary spherocytosis. Pediatr Blood Cancer 2014; 61:29.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Abdullah F, Zhang Y, Camp M, et al. Splenectomy in hereditary spherocytosis: Review of 1,657 patients and application of the pediatric quality indicators. Pediatr Blood Cancer 2009; 52:834.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zhang XH, Fu HX, Xu LP, et al. Allo-hematopoietic stem cell transplantation is a potential treatment for a patient with a combined disorder of hereditary spherocytosis. Chin Med J (Engl) 2012; 125:947.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 7079 Version 46.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26537302" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Anatomy of the red cell membrane skeleton: unanswered questions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32702754" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Red cell membrane disorders: structure meets function.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28447420" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Red cell membrane disorders.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15071790" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Hereditary spherocytosis--defects in proteins that connect the membrane skeleton to the lipid bilayer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8943874" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Characterization of 13 novel band 3 gene defects in hereditary spherocytosis with band 3 deficiency.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8640229" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Ankyrin-1 mutations are a major cause of dominant and recessive hereditary spherocytosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9233560" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Heterogenous band 3 deficiency in hereditary spherocytosis related to different band 3 gene defects.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11936273" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : The pallidin (Pldn) gene and the role of SNARE proteins in melanosome biogenesis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12191018" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Pallidin is a component of a multi-protein complex involved in the biogenesis of lysosome-related organelles.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8808627" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Anion exchanger 1 (band 3) is required to prevent erythrocyte membrane surface loss but not to form the membrane skeleton.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8841202" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Targeted disruption of the murine erythroid band 3 gene results in spherocytosis and severe haemolytic anaemia despite a normal membrane skeleton.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10359562" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Mild spherocytosis and altered red cell ion transport in protein 4. 2-null mice.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8480190" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Ankyrins: structure and function in normal cells and hereditary spherocytes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8621763" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Defective anion transport and marked spherocytosis with membrane instability caused by hereditary total deficiency of red cell band 3 in cattle due to a nonsense mutation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19409822" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Hematologic characterization and chromosomal localization of the novel dominantly inherited mouse hemolytic anemia, neonatal anemia (Nan).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20691777" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Mutation in erythroid specific transcription factor KLF1 causes Hereditary Spherocytosis in the Nan hemolytic anemia mouse model.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30143664" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Mutant KLF1 in Adult Anemic Nan Mice Leads to Profound Transcriptome Changes and Disordered Erythropoiesis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21055716" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : A dominant mutation in the gene encoding the erythroid transcription factor KLF1 causes a congenital dyserythropoietic anemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9192783" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Spectrin St Claude, a splicing mutation of the human alpha-spectrin gene associated with severe poikilocytic anemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8547102" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Beta spectrin PRAGUE: a truncated beta spectrin producing spectrin deficiency, defective spectrin heterodimer self-association and a phenotype of spherocytic elliptocytosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35834292" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Insane in the membrane: A case of hereditary spherocytic pyropoikilocytosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18988878" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Red cell membrane: past, present, and future.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27756835" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : New insights on hereditary erythrocyte membrane defects.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30504335" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Inherited hemolytic anemia: a possessive beginner's guide.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16304353" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Red cell membrane disorders.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9054656" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Frequent de novo mutations of the ANK1 gene mimic a recessive mode of transmission in hereditary spherocytosis: three new ANK1 variants: ankyrins Bari, Napoli II and Anzio.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8703812" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Ankyrin Napoli: a de novo deletional frameshift mutation in exon 16 of ankyrin gene (ANK1) associated with spherocytosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9067504" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Ankyrin Bugey: a de novo deletional frameshift variant in exon 6 of the ankyrin gene associated with spherocytosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9470011" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : High frequency of de novo mutations in ankyrin gene (ANK1) in children with hereditary spherocytosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9609518" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Frequent de novo monoallelic expression of beta-spectrin gene (SPTB) in children with hereditary spherocytosis and isolated spectrin deficiency.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11167781" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Clinical and molecular evaluation of non-dominant hereditary spherocytosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9573679" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Hereditary spherocytosis: from clinical to molecular defects.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10942416" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Severe hereditary spherocytosis and distal renal tubular acidosis associated with the total absence of band 3.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27718309" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Band 3 nullVIENNA , a novel homozygous SLC4A1 p.Ser477X variant causing severe hemolytic anemia, dyserythropoiesis and complete distal renal tubular acidosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31333484" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : The Spectrum of SPTA1-Associated Hereditary Spherocytosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32596782" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : The Human Gene Mutation Database (HGMD®): optimizing its use in a clinical diagnostic or research setting.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12754702" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Human Gene Mutation Database (HGMD): 2003 update.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16223590" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Hematologically important mutations: ankyrin variants in hereditary spherocytosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30227413" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Spectrum of Ankyrin Mutations in Hereditary Spherocytosis: A Case Report and Review of the Literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Development of a comprehensive rapid next-generation sequencing assay for the diagnosis of inherited hemolytic anemia
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8533822" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Hereditary spherocytic anemia with deletion of the short arm of chromosome 8.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7530501" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Mutations of conserved arginines in the membrane domain of erythroid band 3 lead to a decrease in membrane-associated band 3 and to the phenotype of hereditary spherocytosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9326249" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Band 3 Campinas: a novel splicing mutation in the band 3 gene (AE1) associated with hereditary spherocytosis, hyperactivity of Na+/Li+ countertransport and an abnormal renal bicarbonate handling.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8567957" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : A nonsense mutation in the erythrocyte band 3 gene associated with decreased mRNA accumulation in a kindred with dominant hereditary spherocytosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9012689" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Novel band 3 variants (bands 3 Foggia, Napoli I and Napoli II) associated with hereditary spherocytosis and band 3 deficiency: status of the D38A polymorphism within the EPB3 locus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8547122" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Band 3 Chur: a variant associated with band 3-deficient hereditary spherocytosis and substitution in a highly conserved position of transmembrane segment 11.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9266920" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : A variant of the EPB3 gene of the anti-Lepore type in hereditary spherocytosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32436265" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Genotype-phenotype correlation in children with hereditary spherocytosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9207478" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Modulation of clinical expression and band 3 deficiency in hereditary spherocytosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8704215" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Hereditary spherocytosis with band 3 deficiency. Association with a nonsense mutation of the band 3 gene (allele Lyon), and aggravation by a low-expression allele occurring in trans (allele Genas).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2146504" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Molecular defect of the band 3 protein in southeast Asian ovalocytosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1722314" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Deletion in erythrocyte band 3 gene in malaria-resistant Southeast Asian ovalocytosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9312167" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Familial distal renal tubular acidosis is associated with mutations in the red cell anion exchanger (Band 3, AE1) gene.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9600966" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Mutations in the chloride-bicarbonate exchanger gene AE1 cause autosomal dominant but not autosomal recessive distal renal tubular acidosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9497368" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Autosomal dominant distal renal tubular acidosis is associated in three families with heterozygosity for the R589H mutation in the AE1 (band 3) Cl-/HCO3- exchanger.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18174378" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Band 3 Courcouronnes (Ser667Phe): a trafficking mutant differentially rescued by wild-type band 3 and glycophorin A.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20028337" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Band 3 Edmonton I, a novel mutant of the anion exchanger 1 causing spherocytosis and distal renal tubular acidosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19625994" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Compound mutations in human anion exchanger 1 are associated with complete distal renal tubular acidosis and hereditary spherocytosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17941824" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Dominant-negative effect of Southeast Asian ovalocytosis anion exchanger 1 in compound heterozygous distal renal tubular acidosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24094240" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : The Diego blood group system: a review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8471774" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Human erythrocyte protein 4.2 deficiency associated with hemolytic anemia and a homozygous 40glutamic acid--&gt;lysine substitution in the cytoplasmic domain of band 3 (band 3Montefiore).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21257764" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Dual transport properties of anion exchanger 1: the same transmembrane segment is involved in anion exchange and in a cation leak.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16227998" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Monovalent cation leaks in human red cells caused by single amino-acid substitutions in the transport domain of the band 3 chloride-bicarbonate exchanger, AE1.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19261491" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Hereditary stomatocytosis and cation-leaky red cells--recent developments.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29051181" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Disorders of erythrocyte hydration.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19644137" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : A novel erythroid anion exchange variant (Gly796Arg) of hereditary stomatocytosis associated with dyserythropoiesis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3886234" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Hereditary spherocytosis and related disorders.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31602632" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Deciphering molecular heterogeneity of Indian families with hereditary spherocytosis using targeted next-generation sequencing: First South Asian study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9207476" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Characterization of the underlying molecular defect in hereditary spherocytosis associated with spectrin deficiency.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8102379" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Beta spectrin kissimmee: a spectrin variant associated with autosomal dominant hereditary spherocytosis and defective binding to protein 4.1.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9714702" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Hereditary spherocytosis with spectrin deficiency related to null mutations of the beta-spectrin gene.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9450796" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : A 5' splice region G--&gt;C mutation in exon 3 of the human beta-spectrin gene leads to decreased levels of beta-spectrin mRNA and is responsible for dominant hereditary spherocytosis (spectrin Guemene-Penfao).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8675627" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Molecular basis of spectrin deficiency in beta spectrin Durham. A deletion within beta spectrin adjacent to the ankyrin-binding site precludes spectrin attachment to the membrane in hereditary spherocytosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8630421" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Hereditary spherocytosis with spectrin deficiency due to an unstable truncated beta spectrin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19538529" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Novel beta-spectrin mutations in hereditary spherocytosis associated with decreased levels of mRNA.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34093240" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Targeted Next Generation Sequencing and Diagnosis of Congenital Hemolytic Anemias: A Three Years Experience Monocentric Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9067503" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Amino-acid substitution in alpha-spectrin commonly coinherited with nondominant hereditary spherocytosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24895341" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Severe nondominant hereditary spherocytosis due to uniparental isodisomy at the SPTA1 locus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8941647" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Combination of two mutant alpha spectrin alleles underlies a severe spherocytic hemolytic anemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31038472" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Aberrant splicing contributes to severeα-spectrin-linked congenital hemolytic anemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34889366" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Diagnosis and clinical management of red cell membrane disorders.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8635206" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Electron microscopic evidence of impaired intramembrane particles and instability of the cytoskeletal network in band 4.2 deficiency in human red cells.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10406914" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : 4.2 Nippon mutation in a non-Japanese patient with hereditary spherocytosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21275958" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : Compound heterozygosity for two novel mutations in the erythrocyte protein 4.2 gene causing spherocytosis in a Caucasian patient.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1558976" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : An alanine-to-threonine substitution in protein 4.2 cDNA is associated with a Japanese form of hereditary hemolytic anemia (protein 4.2NIPPON).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1558976" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : An alanine-to-threonine substitution in protein 4.2 cDNA is associated with a Japanese form of hereditary hemolytic anemia (protein 4.2NIPPON).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7819064" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : A novel mutation in the erythrocyte protein 4.2 gene of Japanese patients with hereditary spherocytosis (protein 4.2 Fukuoka).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8547071" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : Band 4.2 Shiga: 317 CGC--&gt;TGC in compound heterozygotes with 142 GCT--&gt;ACT results in band 4.2 deficiency and microspherocytosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8528207" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : A novel mutation causing an aberrant splicing in the protein 4.2 gene associated with hereditary spherocytosis (protein 4.2Notame).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20179084" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : Investigating the key membrane protein changes during in vitro erythropoiesis of protein 4.2 (-) cells (mutations Chartres 1 and 2).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1378323" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : Band 3 Tuscaloosa: Pro327----Arg327 substitution in the cytoplasmic domain of erythrocyte band 3 protein associated with spherocytic hemolytic anemia and partial deficiency of protein 4.2.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9734643" id="rid91" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          92 : Homozygous missense mutation (band 3 Fukuoka: G130R): a mild form of hereditary spherocytosis with near-normal band 3 content and minimal changes of membrane ultrastructure despite moderate protein 4.2 deficiency.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9401060" id="rid92" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          93 : Total absence of protein 4.2 and partial deficiency of band 3 in hereditary spherocytosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16411779" id="rid93" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          94 : Structure and stability of hereditary spherocytosis mutants of the cytosolic domain of the erythrocyte anion exchanger 1 protein.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20339087" id="rid94" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          95 : Hereditary spherocytosis and hereditary elliptocytosis: aberrant protein sorting during erythroblast enucleation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18341630" id="rid95" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          96 : Disorders of red cell membrane.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18940465" id="rid96" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          97 : Hereditary spherocytosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15287938" id="rid97" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          98 : Guidelines for the diagnosis and management of hereditary spherocytosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11698268" id="rid98" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          99 : Temporal differences in membrane loss lead to distinct reticulocyte features in hereditary spherocytosis and in immune hemolytic anemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11698268" id="rid99" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          100 : Temporal differences in membrane loss lead to distinct reticulocyte features in hereditary spherocytosis and in immune hemolytic anemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9256290" id="rid100" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          101 : Membrane cation and anion transport activities in erythrocytes of hereditary spherocytosis: effects of different membrane protein defects.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7492791" id="rid101" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          102 : Increased cation permeability in mutant mouse red blood cells with defective membrane skeletons.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22510876" id="rid102" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          103 : Quantitative assessment of sensing and sequestration of spherocytic erythrocytes by the human spleen.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32777816" id="rid103" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          104 : Hemolysis in the spleen drives erythrocyte turnover.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7070419" id="rid104" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          105 : Deficient red-cell spectrin in severe, recessively inherited spherocytosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22791773" id="rid105" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          106 : What does the spleen see?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30190436" id="rid106" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          107 : Mechanics of diseased red blood cells in human spleen and consequences for hereditary blood disorders.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8611472" id="rid107" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          108 : Cytoskeletal behaviour in spectrin and in band 3 deficient spherocytic red cells: evidence for differentiated splenic conditioning role.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25388786" id="rid108" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          109 : Partial pyruvate kinase deficiency aggravates the phenotypic expression of band 3 deficiency in a family with hereditary spherocytosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31273765" id="rid109" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          110 : Hereditary spherocytosis is associated with decreased pyruvate kinase activity due to impaired structural integrity of the red blood cell membrane.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1554800" id="rid110" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          111 : Prevalence of increased osmotic fragility of erythrocytes in German blood donors: screening using a modified glycerol lysis test.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16728359" id="rid111" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          112 : Incidence of hereditary spherocytosis in a population of jaundiced neonates.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31723846" id="rid112" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          113 : The Complexity of Genotype-Phenotype Correlations in Hereditary Spherocytosis: A Cohort of 95 Patients: Genotype-Phenotype Correlation in Hereditary Spherocytosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1954389" id="rid113" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          114 : Deficiency of alpha-spectrin synthesis in burst-forming units-erythroid in lethal hereditary spherocytosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3348251" id="rid114" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          115 : Hereditary spherocytosis in the elderly.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2391596" id="rid115" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          116 : Variable clinical severity of hereditary spherocytosis: relation to erythrocytic spectrin concentration, osmotic fragility, and autohemolysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10498597" id="rid116" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          117 : Coinheritance of Gilbert syndrome increases the risk for developing gallstones in patients with hereditary spherocytosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22055020" id="rid117" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          118 : Guidelines for the diagnosis and management of hereditary spherocytosis--2011 update.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26009624" id="rid118" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          119 : A pediatrician's practical guide to diagnosing and treating hereditary spherocytosis in neonates.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10627440" id="rid119" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          120 : Natural history of hereditary spherocytosis during the first year of life.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6886914" id="rid120" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          121 : Diagnosis of hereditary spherocytosis in newborn infants.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11920183" id="rid121" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          122 : Recombinant erythropoietin therapy as an alternative to blood transfusions in infants with hereditary spherocytosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33899219" id="rid122" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          123 : Acute human parvovirus B19 infection triggers immune-mediated transient bone marrow failure syndrome, extreme direct hyperbilirubinaemia and acute hepatitis in patients with hereditary haemolytic anaemias: multicentre prospective pathophysiological study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32885142" id="rid123" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          124 : Recommendations for Pregnancy in Rare Inherited Anemias.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17209211" id="rid124" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          125 : Folate and neural tube defects.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34188052" id="rid125" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          126 : Iron-dependent apoptosis causes embryotoxicity in inflamed and obese pregnancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2239921" id="rid126" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          127 : Massive mediastinal extramedullary hematopoiesis in hereditary spherocytosis: a case report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21517821" id="rid127" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          128 : Extramedullary haematopoiesis secondary to hereditary spherocytosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30965318" id="rid128" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          129 : Mild Hereditary Spherocytosis without Accompanying Hereditary Haemochromatosis: An Unrecognised Cause of Iron Overload.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21206415" id="rid129" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          130 : Hereditary spherocytosis with leg ulcers healing after splenectomy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17949526" id="rid130" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          131 : Stuttering priapism associated with hereditary spherocytosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19948573" id="rid131" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          132 : Hereditary spherocytosis in neonates with hyperbilirubinemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14315658" id="rid132" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          133 : HEREDITARY SPHEROCYTOSIS; CLINICAL FAMILY STUDIES.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14926818" id="rid133" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          134 : Incidence of gallbladder disease in chronic hemolytic anemia (spherocytosis).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24650472" id="rid134" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          135 : Synchronous splenectomy during cholecystectomy for hereditary spherocytosis: is it really necessary?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19388926" id="rid135" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          136 : Risks and benefits of splenectomy versus no splenectomy for hereditary spherocytosis--a personal view.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18485083" id="rid136" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          137 : Delayed adverse vascular events after splenectomy in hereditary spherocytosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24411920" id="rid137" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          138 : Direct antiglobulin ("Coombs") test-negative autoimmune hemolytic anemia: a review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27913548" id="rid138" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          139 : Warm antibody autoimmune hemolytic anemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33435309" id="rid139" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          140 : Autoimmune Hemolytic Anemia in the Pediatric Setting.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25790109" id="rid140" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          141 : ICSH guidelines for the laboratory diagnosis of nonimmune hereditary red cell membrane disorders.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2961992" id="rid141" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          142 : Partial ankyrin and spectrin deficiency in severe, atypical hereditary spherocytosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8266114" id="rid142" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          143 : Clinical expression and laboratory detection of red blood cell membrane protein mutations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9202619" id="rid143" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          144 : Screening for hereditary spherocytosis by use of automated erythrocyte indexes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23023797" id="rid144" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          145 : Delay in the measurement of eosin-5′-maleimide (EMA) binding does not affect the test result for the diagnosis of hereditary spherocytosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23023797" id="rid145" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          146 : Delay in the measurement of eosin-5′-maleimide (EMA) binding does not affect the test result for the diagnosis of hereditary spherocytosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22058213" id="rid146" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          147 : Diagnostic power of laboratory tests for hereditary spherocytosis: a comparison study in 150 patients grouped according to molecular and clinical characteristics.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11122157" id="rid147" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          148 : Rapid flow cytometric test for the diagnosis of membrane cytoskeleton-associated haemolytic anaemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22488885" id="rid148" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          149 : Use of capillary blood to diagnose hereditary spherocytosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25357094" id="rid149" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          150 : Evaluating eosin-5-maleimide binding as a diagnostic test for hereditary spherocytosis in newborn infants.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28466540" id="rid150" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          151 : Usefulness of the EMA flow cytometric test in the diagnosis of hereditary spherocytosis post-transfusion.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18782334" id="rid151" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          152 : Evaluation of eosin-5-maleimide flow cytometric test in diagnosis of hereditary spherocytosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17016037" id="rid152" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          153 : Flow cytometry as a diagnostic tool for hereditary spherocytosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21080168" id="rid153" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          154 : A prospective study to assess the predictive value for hereditary spherocytosis using five laboratory tests (cryohemolysis test, eosin-5'-maleimide flow cytometry, osmotic fragility test, autohemolysis test, and SDS-PAGE) on 50 hereditary spherocytosis families in Argentina.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30548189" id="rid154" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          155 : Eosin-5'-maleimide binding test-Do we use appropriate reference values to detect hereditary spherocytosis in neonates?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26603718" id="rid155" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          156 : Diagnostic tool for red blood cell membrane disorders: Assessment of a new generation ektacytometer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8783633" id="rid156" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          157 : Red cell abnormalities in hereditary spherocytosis: relevance to diagnosis and understanding of the variable expression of clinical severity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7397390" id="rid157" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          158 : Automated ektacytometry: a new method of measuring red cell deformability and red cell indices.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6156955" id="rid158" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          159 : Analysis of factors regulating erythrocyte deformability.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29755372" id="rid159" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          160 : Use of Laser Assisted Optical Rotational Cell Analyzer (LoRRca MaxSis) in the Diagnosis of RBC Membrane Disorders, Enzyme Defects, and Congenital Dyserythropoietic Anemias: A Monocentric Study on 202 Patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3356239" id="rid160" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          161 : Comparison of acidified glycerol lysis test, Pink test and osmotic fragility test in hereditary spherocytosis: effect of incubation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3631064" id="rid161" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          162 : Modified end-point glycerol hemolysis assay as a screening test for hereditary spherocytosis that requires no venipuncture.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9662272" id="rid162" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          163 : Cryohemolysis for the detection of hereditary spherocytosis: correlation studies with osmotic fragility and autohemolysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9204617" id="rid163" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          164 : Usefulness of cryohemolysis test in the diagnosis of hereditary spherocytosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28550188" id="rid164" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          165 : Recommendations regarding splenectomy in hereditary hemolytic anemias.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8639421" id="rid165" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          166 : Thrombo-embolic disease after splenectomy for hereditary stomatocytosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30655378" id="rid166" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          167 : Clinical and biological features in PIEZO1-hereditary xerocytosis and Gardos channelopathy: a retrospective series of 126 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26273436" id="rid167" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          168 : Infantile pyknocytosis, a rare cause of hemolytic anemia in newborns: report of two cases in twin girls and literature overview.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/869997" id="rid168" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          169 : Congenital dyserythropoietic anaemia, types I and II: aberrant pattern of erythrocyte membrane proteins in CDA II, as revealed by two-dimensional polyacrylamide gel electrophoresis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32391969" id="rid169" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          170 : How I approach hereditary hemolytic anemia and splenectomy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2782557" id="rid170" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          171 : Splenectomy in mild hereditary spherocytosis: is it worth the risk?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14500222" id="rid171" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          172 : Partial splenic embolization for the treatment of hereditary spherocytosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26773041" id="rid172" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          173 : Long-term follow-up of subtotal splenectomy for hereditary spherocytosis: a single-center study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25382665" id="rid173" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          174 : Clinical outcomes of splenectomy in children: report of the splenectomy in congenital hemolytic anemia registry.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26613837" id="rid174" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          175 : Hematologic outcomes after total splenectomy and partial splenectomy for congenital hemolytic anemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21238662" id="rid175" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          176 : Partial splenectomy for hereditary spherocytosis: a multi-institutional review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20713220" id="rid176" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          177 : Institutional experience with laparoscopic partial splenectomy for hereditary spherocytosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28417547" id="rid177" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          178 : A long-term follow-up study of subtotal splenectomy in children with hereditary spherocytosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29506817" id="rid178" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          179 : Results after laparoscopic partial splenectomy for children with hereditary spherocytosis: Are outcomes influenced by genetic mutation?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24632695" id="rid179" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          180 : Hereditary spherocytosis in children: profile and post-splenectomy outcome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23049376" id="rid180" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          181 : Clinical course of 63 children with hereditary spherocytosis: a retrospective study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36312509" id="rid181" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          182 : Cholecystectomy for asymptomatic gallstones: Markov decision tree analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14467944" id="rid182" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          183 : Relapse in hereditary spherocytosis with proven splenunculus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9802800" id="rid183" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          184 : Laparoscopy improves outcomes for pediatric splenectomy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9780987" id="rid184" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          185 : A case controlled comparison of open and laparoscopic splenectomy in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11821831" id="rid185" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          186 : Laparoscopic splenectomy for hematologic diseases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21626013" id="rid186" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          187 : Contemporary pediatric splenectomy: continuing controversies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17893505" id="rid187" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          188 : Laparoscopic splenic procedures in children: experience in 231 children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10986763" id="rid188" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          189 : [Laparoscopic splenectomy for hematologic diseases. Study of 275 cases. French Society of Laparoscopic Surgery].
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30155296" id="rid189" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          190 : Challenges and Results of Laparoscopic Splenectomy for Hematological Diseases in a Developing Country.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11154215" id="rid190" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          191 : Long-term evaluation of the beneficial effect of subtotal splenectomy for management of hereditary spherocytosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9107531" id="rid191" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          192 : Effectiveness of partial splenectomy in hereditary spherocytosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15621989" id="rid192" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          193 : Near-total splenectomy: a new technique for the management of hereditary spherocytosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16487182" id="rid193" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          194 : Near-total splenectomy for hereditary spherocytosis: clinical prospects in relation to disease severity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17024531" id="rid194" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          195 : A laparoscopic approach to partial splenectomy for children with hereditary spherocytosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18381098" id="rid195" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          196 : Partial splenectomy for hereditary spherocytosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18779001" id="rid196" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          197 : Laparoscopic partial vs total splenectomy in children with hereditary spherocytosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22476842" id="rid197" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          198 : Laparoscopic versus robotic subtotal splenectomy in hereditary spherocytosis. Potential advantages and limits of an expensive approach.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16544076" id="rid198" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          199 : Laparoscopic subtotal splenectomy in hereditary spherocytosis : to preserve the upper or the lower pole of the spleen?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30767061" id="rid199" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          200 : Feasibility and Safety of Laparoscopic Partial Splenectomy: A Systematic Review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3785322" id="rid200" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          201 : Inheritance pattern and clinical response to splenectomy as a reflection of erythrocyte spectrin deficiency in hereditary spherocytosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31571940" id="rid201" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          202 : Post-splenectomy sepsis: preventative strategies, challenges, and solutions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4596312" id="rid202" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          203 : Postsplenectomy sepsis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7810936" id="rid203" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          204 : Estimating the risk for sepsis after splenectomy in hereditary spherocytosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10442589" id="rid204" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          205 : The morbidity and mortality of pediatric splenectomy: does prophylaxis make a difference?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2058391" id="rid205" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          206 : Pneumococcal infections in splenectomized children are preventable.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27118929" id="rid206" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          207 : Giant right ventricular outflow tract thrombus in hereditary spherocytosis: a case report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19373154" id="rid207" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          208 : Dural venous thrombosis following splenectomy in a patient with hereditary spherocytosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9400518" id="rid208" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          209 : Spherocytosis, splenectomy, strokes, and heat attacks.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17497044" id="rid209" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          210 : Pulmonary arterial hypertension after splenectomy for hereditary spherocytosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1936235" id="rid210" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          211 : Spherocytosis and pulmonary hypertension coincidental occurrence or causal relationship?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9423823" id="rid211" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          212 : Hereditary spherocytosis, thrombocytosis, and chronic pulmonary emboli: a case report and review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6962715" id="rid212" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          213 : Venous thrombosis in haemoglobin H disease after splenectomy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/69206" id="rid213" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          214 : Splenectomy and subsequent mortality in veterans of the 1939-45 war.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19057057" id="rid214" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          215 : Protein C deficiency leading to pulmonary thromboembolism in a patient with hereditary spherocytosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24038836" id="rid215" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          216 : Risk factors for thromboembolism and pulmonary artery hypertension following splenectomy in children with hereditary spherocytosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19214973" id="rid216" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          217 : Splenectomy in hereditary spherocytosis: Review of 1,657 patients and application of the pediatric quality indicators.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22490603" id="rid217" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          218 : Allo-hematopoietic stem cell transplantation is a potential treatment for a patient with a combined disorder of hereditary spherocytosis.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
